

Synthesis of C-linked analogues of β -D-galactopyranosyl-(1 $\rightarrow$ 3)-D-galactopyranosides and of β -D-galactopyranosyl-(1 $\rightarrow$ 3)-D-galactal

Raynald Demange,[†] Loay Awad and Pierre Vogel*

Laboratoire de glycochimie et de synthèse asymétrique, Swiss Federal Institute of Technology (EPFL), BCH, CH-1015 Lausanne-Dorigny, Switzerland

Received 17 August 2004; accepted 30 September 2004

Available online 22 October 2004

Abstract—C-linked disaccharide derivatives mimicking *O*- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-D-galactopyranosides (end groups in Core-B structures of biologically important proteoglycans) have been obtained from isolevoglucosenone and β -D-galactopyranosylcarbaldehyde derivatives. The β -D-galactopyranosyl-(1 $\rightarrow$ 3)-CH(OH)-D-galactal derivatives **3a** (4,6-di-*O*-acetyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-D-glycero-L-manno-heptitol-1-*C*-yl]-3-deoxy-D-galactal), **3b** (4,6-di-*O*-benzyl-3-*C*-[(1*R*)-2,6-anhydro-1,3,4,5,7-penta-*O*-benzyl-D-glycero-L-manno-heptitol-1-*C*-yl]-3-deoxy-D-galactal) and the β -D-galactopyranosyl-(1 $\rightarrow$ 3)-CH₂-D-galactal **3c** (4,6-*O*-diacetyl-3-*C*-[6-*O*-acetyl-2,3,4-tri-*O*-(*tert*-butyl)dimethylsilyl]- β -D-galactopyranosylmethyl]-3-deoxy-D-galactal) have been prepared. One of them, **3a**, has been shown to be a suitable agent for the *O*-glycosidation and the construction of glycoconjugates bearing the β -D-Galp-(1 $\rightarrow$ 3)-CH(OH)-D-Galp-*O* moiety.

© 2004 Elsevier Ltd. All rights reserved.


1. Introduction

Carbohydrates regulate the cell/cell¹ and cell/invaser² interactions, and play a crucial role in the construction of multicellular organs and organisms. With a growing understanding of the precise function that cell-surface carbohydrates play in disorders such as inflammation, viral and bacterial infections, to cancer, numerous carbohydrate analogues have now been developed and entered into clinical studies.³ Disaccharide mimetics such as C-linked disaccharides and oligosaccharides containing them offer the advantage of being resistant to acidic and enzymatic hydrolysis.^{4,5} They are potential inhibitors of glycosidases and glycosyltransferases.⁶ The disaccharide *O*- β -D-galactopyranosyl-(1 $\rightarrow$ 3)-*O*- β -D-galactopyranosyl **1** is found as an end group in Core-B structures of a large number of proteoglycans⁷ and has been isolated from a variety of other sources.⁸ We report herein efficient syntheses of protected forms **2** of C-linked analogues of **1**, including the β -D-galactopyranosyl-(1 $\rightarrow$ 3)-D-galactal derivatives **3**, compounds suitable for *O*-glycosidation⁹ and for the preparation of C-glyco-

sides.^{10,11} An isomer of **2** (α -methyl α -galactopyranosyl, (*S*)-hydroxymethylene linker) had been prepared already in 1992 by Schmidt and Beyerbach.¹² Their method involved the direct lithiation of 3,4,6-*O*-tribenzyl 2-phenylsulfinyl-D-galactal with methyl 2,4,6-*O*-tribenzyl-3-deoxy- α -D-galactopyranosyl bearing a β -carbaldehyde group at C(3). We had applied the Oshima–Nozaki coupling reaction of enones and aldehydes¹³ to a 2,3,4,6-*O*-tetrabenzyl- β -D-glucopyranosylcarbaldehyde and isolevoglucosenone **4**¹⁴ and obtained 2,3-anhydro-3-*C*-[(1*S*)-2,6-anhydro-D-glycero-D-gulo-heptitol-1-*C*-yl]- β -D-gulopyranose¹⁵ and a fluorinated derivative.¹⁶ We will show now that 2,3,4,6-*O*-tetrabenzyl-**5a** and 2,3,4,6-*O*-tetra [(*tert*-butyl)dimethylsilyl]- β -D-galactopyranosylcarbaldehyde **5b**^{17,18} can be condensed with isolevoglucosenone **4** (Scheme 1) to produce enones **6a** and **6b**, respectively (Baylis–Hillmann type of products) which can be readily converted into C-linked analogues of β -D-galactopyranosyl-(1 $\rightarrow$ 3)-D-galactal derivatives **3a–3c**. The carbon linker is a hydroxymethylene group in **3a** and **3b**, and a methylene group in **3c**. Galactal **3b** was converted into β -D-galactopyranosyl-(1 $\rightarrow$ 3)-CH(OH)-D-galactopyranosides **2** and **17** and into β -D-galactopyranosyl-(1 $\rightarrow$ 3)-CH(OH)-D-talactopyranosides **16**. Galactal **3a** was converted into β -D-galactopyranosyl-(1 $\rightarrow$ 3)-CH(OH)-2-deoxy-D-lyxo pyranoside α -*O*-conjugated with L-serine **21**.

* Corresponding author. Tel.: +41 216939371; fax: +41 216939375; e-mail: pierre.vogel@epfl.ch

[†] Address: SICPA, CH 1008 Prilly.



2. Results and discussion


Slow addition of Et_2AlI in solution in toluene to a mixture of **4** and aldehydes **5a** and **5b** in CH_2Cl_2 (-80°C) led to the formation of enones **6a** and **6b** in 73% and 95% yield, respectively. These reactions imply the formation of aluminum enolate **7**, which adds to aldehydes **5a** and **5b** following the Zimmerman–Traxler model **8**¹⁹ (steric factors control the diastereoselectivity) giving iodo-aldols **9** which are unstable and eliminate HI during aqueous work-up (Scheme 1).

Attempts to reduce both the C=C and C=O double bonds of enones **6a** and **6b** by direct methods [NaBH_4 , $\text{LiAlH}(\text{t-BuS})_3$, cat. hydrogenation followed by hydride reduction] led to mixtures of diastereomeric products. Addition of thiophenol to **6a** catalyzed by Et_3N generated a single adduct **10** that could not be isolated because the thiophenol was eliminated readily at 20°C . Thus the crude adduct **10** was treated directly with NaBH_4 at 0°C to produce a single diol **11** that was isolated in 81% yield.¹⁵ Desulfurization of **11** with Raney nickel in THF gave diol **12** (87% yield). It was converted into its acetone **13** (62%) under standard conditions. The 2-D-NOESY ^1H NMR spectrum of **13** confirmed its structure and of its precursor ($^3J_{3,4} = 8.2\text{ Hz}$). Moreover, its ^{13}C NMR spectrum showed $\delta_{\text{C}}(\text{Me}) = 25.5, 27.5\text{ ppm}$, typical for a 1,4-*anti*-disubstitution of the 1,3-dioxane moiety.²⁰ A Birch reduction of the benzyl ethers of **12**, followed by acetylation provided hexaacetate **14** in 88% yield. Treatment of **14** with Ac_2O and CF_3COOH gave a 1:0.3 mixture of α/β pyranosides **15a** and **15b**. When this mixture was heated under reflux


in toluene containing silica gel, a smooth elimination of acetic acid occurred with the formation of galactal **3a** isolated in 82% yield after flash chromatography. Exchange of the acetyl groups for benzyl groups was done by treating **3a** with $\text{MeOH}/\text{Na}_2\text{CO}_3$ at 20°C for 90 min, followed by solvent removal and reaction of the polyol with NaH in DMF and then with benzyl bromide and Bu_4NI . This gave **3b** in 76% yield for the two steps.

Galactal **3b** reacted with dimethyldioxirane in acetone at 0°C . The unstable intermediate epoxide (*Brigl* anhydride) reacted with MeOH to give semi-protected [free at OH at C(2)] methyl β -D-galactopyranoside, which was not isolated but benzylated under standard conditions to furnish the perbenzylated C-disaccharide **2** (Scheme 2) in 71% yield (three steps). The ^1H NMR spectrum of **2** (vicinal H/H coupling constants) proved its structure. Interestingly, when **3b** was epoxidized with *meta*-chloroperbenzoic acid (Scheme 3), the intermediate epoxide reacted with MeOH to give the semi-protected C-disaccharide **16** in 52% yield together with 20% of **17** (Scheme 2). This is a C-linked analogue of (β -D-galactopyranosyl) (1 $\rightarrow$ 3)-(methyl α -D-talopyranoside). The preferred α -face epoxidation of galactal **3b** with dimethyldioxirane is to be expected for steric reasons. The preferred β -face epoxidation of **3b** with *m*-CPBA can be attributed to hydrogen bridging of the peracid with the 4- or 6-benzyloxy group. To further test the usefulness of our C-galactopyranosyl(1 $\rightarrow$ 3)galactal derivatives, we reacted peracetate **3a** with *Z*-Ser-OBn and Fmoc-Ser-OBn (semiprotected forms of L-serine) in the presence of $\text{I}(\text{sym-collidine})_2\text{ClO}_4$ (Lemieux's,²¹ Thiem's²² haloglycosidations). This produced iodo-talopyranosides **18** (72%) and **19** (70%), respectively. Attempts to displace the iodide of **18** and **19** by all kinds of azides (NaN_3/DMF , LiN_3/DMF , tetramethylguanidium azide/DMF, $\text{Me}_3\text{SiN}_3/\text{Bu}_4\text{NF}/\text{THF}$, azidoadamantane/DMF) led to products of decomposition and/or to the α -D-threo-hex-2-enopyranoside **20**.²³ Radical dehalogenation²⁴ of **18** with $\text{Bu}_3\text{SnH}/\text{AIBN}$ generated the 2-deoxy- α -galactopyranoside **21** in 72% yield (Scheme 3).²⁵


We have also explored the possibility of generating β -D-galactopyranosyl-C(1 $\rightarrow$ 3)galactal, in which there is a carbon linker in a methylene rather than a hydroxymethylene group. In the presence of Raney nickel in



Scheme 1.




Scheme 2.



Scheme 3.

THF, the TBS-protected C-galactoside **6b** was reduced quantitatively into a mixture of aldols from which **22** and **23** were isolated (flash chromatography) in 57% and 43% yield, respectively. The crude mixture of **22** and **23** was treated with $\text{CH}_3\text{SO}_2\text{Cl}/\text{pyridine}$ and a catalytical amount of DMAP. This led to the formation of a mixture of unstable enones **24** that were not isolated

but treated with Raney nickel in aqueous THF at 20°C . This produced a mixture of ketones from which pure **25** and **26** were isolated in 43% and 44% yield, respectively. Reduction of **25** with LiBH_4 in THF gave alcohol **27** in 79% yield, the structure of which (1,6-anhydro-2-deoxy-D-*lyxo* configuration) was given by its ^1H NMR spectrum. Treatment of **27** with triethylsilyl



Scheme 4.

trifluoromethanesulfonate and acetic anhydride ring-opened the 1,6-anhydro moiety and acetylated the D-lyxose derivative without formation of furanosides. The mixture of α - and β -pyranosides **28 α,β** thus obtained, was not purified but directly treated with silica gel in benzene heated under reflux. This produced the C-linked analogue of β -D-galactopyranosyl-(1 $\rightarrow$ 3)-D-galactal **3c** in 60% yield (Scheme 4).

3. Conclusion

The Oshima–Nozaki condensation of β -D-galactopyranosylcarbaldehyde derivatives with isolevoglucosenone has allowed the efficient and highly stereoselective synthesis of C-linked disaccharides mimicking β -D-Galp(1 $\rightarrow$ 3)-D-Galp. Useful β -D-galactopyranosyl(1 $\rightarrow$ 3)-CH(OH)-galactal and β -D-galactopyranosyl(1 $\rightarrow$ 3)-CH₂-D-galactal derivatives have been prepared and shown to be suitable for further derivatization and O-glycosidations.

4. Experimental

4.1. General

See Ref. 25; THF and Et₂O were distilled from sodium and benzophenone; toluene from CaH₂; MeOH from magnesium. Electrospray mass analyses were recorded on a Finnigan MAT.SSQ710C spectrometer in the positive ionization mode. High resolution FAB mass spectra were recorded on a FAB-LSIMS (University of Seville, Spain). Elemental analyses were performed by the Ilse Beetz Laboratory, Kronach, Germany. Signal assignments in ¹H NMR spectra are confirmed by 2D-COSY and NOESY spectra.

4.2. 1,6-Anhydro-3-C-[(1R)-2,6-anhydro-3,4,5,7-tetra-O-benzyl-D-glycero-L-manno-heptitol-1-C-yl]-2,3-dideoxy- β -D-glycero-hex-2-en-4-ulopyranose 6a

A solution of Et₂AlI (1 M) in toluene (8.5 mL, 8.5 mmol) was added dropwise in 90 min to a stirred solution of aldehyde **5**¹⁷ (3.53 g, 6.4 mmol) and isolevoglucosenone **4** (1.21 g, 9.5 mmol) in anhydrous CH₂Cl₂ (24 mL) cooled to -80°C under an Ar atmosphere. After stirring at -80°C for 19 h, the cooling bath was removed and Et₂O (80 mL) and then 1 M aq HCl (60 mL) added under vigorous stirring (red mixture becomes yellowish). After the addition of H₂O (50 mL), the aqueous phase was extracted with Et₂O (3 $\times$ 50 mL). The combined organic phases were washed with brine (100 mL) and dried over MgSO₄. Solvent evaporation, FC (8:2 then 7:3 light petroleum/EtOAc) afforded 3.17 g (73%) of a white solid; mp 46–48 $^{\circ}\text{C}$. $[\alpha]_{589}^{25} = +78$, $[\alpha]_{546}^{25} = +52$, $[\alpha]_{435}^{25} = +225$, $[\alpha]_{405}^{25} = +573$ (c 0.12, CHCl₃). UV (MeCN) 243 (6000), 213 (18500). IR (KBr) 3420, 3030, 2870, 1695, 1455, 1365, 1095, 910, 735, 700 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.25 (m, 20H, ArH), 7.04 (dd, ³J_{1,2} = 3.4, ⁴J_{1',2} = 1.4, H-2), 5.75 (d, ³J_{1,2} = 3.4, H-1), 4.98–4.35 (m, 9H, 4 O-CH₂-Ph, H-1'), 4.66 (dd, ³J_{5,6exo} = 6.1, ³J_{5,6endo} = 1.1, H-5), 4.15 (dd, ³J_{3',4'} = 9.5, ³J_{2',3'} = 9.5, H-3'), 3.92–3.88 (m, 2H, H-5', H_{exo}-6), 3.64 (dd, ³J_{3',4'} = 9.5, ³J_{4',5'} = 2.7, H-4'), 3.58 (dd, ³J_{2',3'} = 9.5, ³J_{1',2'} = 1.5, H-2'), 3.51 (dd, ²J = 8.2, ³J_{5,6endo} = 1.1, H_{endo}-6), 3.48–3.45 (m, 3H, H-6', H₂-7'). ¹³C NMR (100.6 MHz, CDCl₃) δ 194.5 (s, C-4), 142.1 (d, 165, C-2), 138.5, 138.4, 138.2, 137.8, 137.8 (5s, 4C_{arom}, C-3), 128.4–127.5 (20d, CH_{arom}), 96.8 (d, 177, C-1), 84.6 (d, 138, C-4'), 79.2 (d, 160, C-5), 79.0 (d, 141, C-2'), 77.3 (d, 143, C-6'), 75.1 (t, 142, O-CH₂-Ph), 74.5 (t, 143, O-CH₂-Ph), 74.5 (d, 142, C-3'), 74.0 (d, 144, C-5'), 73.4 (t, 141, O-CH₂-Ph), 72.4 (t, 142, O-CH₂-Ph), 69.3 (t, 142, C-7'),

66.0 (d, 147, C-1'), 62.2 (t, 154, C-6). CI-MS (NH₃) *m/z* 697 (1, [M+18]⁺), 570 (1), 451 (1), 181 (4), 91 (71), 83 (100). Anal. Calcd for C₄₁H₄₂O₉: C, 72.55; H, 6.24. Found: C, 72.50; H 6.28.

4.3. 1,6-Anhydro-3-C-[(1R)-2,6-anhydro-3,4,5,7-tetra-O-benzyl-D-glycero-L-manno-heptitol-1-C-yl]-2,3-dideoxy-2-phenylthio-β-D-galactopyranose 11

Triethylamine (61 μL, 0.43 mmol) was added to a solution of enone **6** (1.42 g, 2.1 mmol) and thiophenol (0.24 mL, 2.3 mmol) in 9 mL of CH₂Cl₂ cooled to 0°C. The reaction mixture was stirred at 0°C for 1 h at which point 9 mL of MeOH and 164 mg of NaBH₄ (4.3 mmol) were added and the reaction mixture stirred for 2 h at 0°C. Then, CH₂Cl₂ (30 mL) and 1 M aq HCl (6 mL) were added under stirring. After the addition of H₂O (30 mL), the aqueous phase was extracted with CH₂Cl₂ (3 × 20 mL). The combined organic phases were washed with a satd aq soln of NaHCO₃ (40 mL), brine (40 mL) and dried over MgSO₄. Solvent evaporation, FC (7:3 light petroleum ether/EtOAc) afforded 1.33 g (81%) of **11**, colorless oil. $[\alpha]_{589}^{25} = -15$, $[\alpha]_{546}^{25} = -19$, $[\alpha]_{435}^{25} = -34$, $[\alpha]_{405}^{25} = -42$ (c 0.27, CHCl₃). UV (MeCN) 255 (8300), 216 (18600). IR (film) 3375, 3030, 2870, 1455, 1365, 1210, 1115, 910, 735, 695 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.42–7.18 (m, 25H, ArH), 5.60 (s, H-1), 4.95–4.39 (m, 8H, 4 OCH₂Ph), 4.57–4.52 (m, 2H, H-1', H-C4), 4.36 (dd, ³J_{5,6_{exo}} = 5.3, ³J_{4,5} = 5.3, H-5), 4.17 (d, ²J = 7.7, H_{endo}-6), 4.03 (dd, ³J_{3',4'} = 9.4, ³J_{2',3'} = 9.4, H-3'), 3.87 (d, ³J_{4',5'} = 2.5, H-5'), 3.53 (dd, ²J = 7.7, ³J_{5,6_{exo}} = 5.3, H_{exo}-6), 3.51 (dd, ³J_{3',4'} = 9.4, ³J_{4',5'} = 2.5, H-4'), 3.38–3.36 (m, 2H, H₂-7'), 3.29–3.27 (m, 2H, H-2, H-6'), 3.07 (d, ³J_{2',3'} = 9.4, H-2'), 2.20–2.15 (m, H-3). ¹³C NMR (100.6 MHz, CDCl₃) δ 138.4, 138.2, 137.9, 137.5, 134.6 (5s, 5 C_{arom}), 132.3–127.4 (25d, CH_{arom}), 102.9 (d, 177, C-1), 84.6 (d, 137, C-4'), 79.2 (d, 141, C-2'), 76.6 (d, 145, C-6'), 75.7 (t, 142, OCH₂Ph), 74.8 (d, 158, C-5), 74.4 (t, 145, OCH₂Ph), 74.2 (d, 142, C-3'), 73.6 (t, 141, OCH₂Ph), 73.2 (d, 143, C-5'), 72.4 (t, 142, OCH₂Ph), 69.9, 67.2 (2d, 147, 149, C-1', C-4), 68.5 (t, 144, C-7'), 62.9 (t, 152, C-6), 50.8 (d, 144, C-2), 41.4 (d, 131, C-3). CI-MS (NH₃) *m/z* 792 (4, [M+1]⁺), 682 (4), 593 (3), 399 (3), 253 (4), 181 (8), 91 (100). Anal. Calcd for C₄₇H₅₀O₉S: C, 71.37; H, 6.37. Found: C, 71.38; H, 6.42.

4.4. 1,6-Anhydro-3-C-[(1R)-2,6-anhydro-3,4,5,7-tetra-O-benzyl-D-glycero-L-manno-heptitol-1-C-yl]-2,3-dideoxy-β-D-lyxo-hexopyranose 12

A solution of **11** (935 mg, 1.18 mmol) in THF (70 mL) was treated with Raney nickel (~7 g) and the suspension stirred for 1 h at 20°C. When the reaction was complete (TLC 1:1 light petroleum ether/EtOAc), the solid was filtered off and washed with EtOAc. The filtrate and the washing were combined and dried over MgSO₄. Solvent evaporation, FC (3:2 light petroleum ether/EtOAc) afforded 701 mg (87%) of **12**, colorless oil. $[\alpha]_{589}^{25} = +3$, $[\alpha]_{546}^{25} = -7$, $[\alpha]_{435}^{25} = -9$, $[\alpha]_{405}^{25} = -12$ (c 0.15, CHCl₃). UV (MeCN) 210 (15300). IR (film) 3390, 3030, 2870, 1455, 1360, 1210, 1105, 865, 735, 695 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.24 (m, 20H, ArH), 5.43

(br s, H-1), 4.92–4.42 (m, 8H, 4OCH₂Ph), 4.40 (br dd, ³J_{4,5} = 5.2, ³J_{5,6_{exo}} = 4.8, H-5), 4.35 (d, ³J_{1',3} = 10.1, H-1'), 4.28 (br dd, ³J_{3,4} = 6.2, ³J_{4,5} = 5.2, H-4), 4.18 (d, ²J = 7.9, H_{endo}-6), 4.08 (dd, ³J_{3',4'} = 9.4, ³J_{2',3'} = 9.4, H-3'), 3.94 (d, ³J_{4',5'} = 2.3, H-5'), 3.64–3.50 (m, 5H, H-4', H-6', H_{exo}-6, H₂-7'), 3.35 (d, ³J_{2',3'} = 9.4, H-2'), 2.31 (dddd, ³J_{1',3} = 10.1, ³J_{2_{endo},3} = 7.2, ³J_{3,4} = 6.2, ³J_{2_{exo},3} = 3.6, H-3), 1.81 (ddd, ²J = 14.7, ³J_{2_{endo},3} = 7.2, ³J_{1,2_{endo}} = 2.4, H_{endo}-2), 1.66 (br dd, ²J = 14.7, ³J_{2_{exo},3} = 3.6, H_{exo}-2). ¹³C NMR (100.6 MHz, CDCl₃) δ 138.5, 138.2, 138.1, 137.7 (4s, 4C_{arom}), 128.5–127.5 (20d, CH_{arom}), 99.9 (d, 169, C-1), 84.6 (d, 137, C-4'), 78.4 (d, 142, C-2'), 77.0 (d, 143, C-6'), 75.5 (t, 145, OCH₂Ph), 75.3 (d, 157, C-5), 74.4 (t, 144, OCH₂Ph), 74.1 (d, 147, C-3'), 73.6 (t, 142, OCH₂Ph), 73.5 (d, 142, C-5'), 72.4 (t, 141, OCH₂Ph), 71.2 (d, 148, C-1'), 69.3 (d, 147, C-4), 68.9 (t, 144, C-7'), 63.9 (t, 151, C-6), 35.1 (d, 132, C-3), 32.2 (t, 128, C-2). CI-MS (NH₃) *m/z* 701 (3, [M+18]⁺), 684 (2, [M+1]⁺), 633 (2), 581 (1), 485 (1), 181 (8), 91 (100). Anal. Calcd for C₄₁H₄₆O₉: C, 72.11; H, 6.79. Found: C, 72.16; H, 6.77.

4.5. 1,6-Anhydro-3-C-[(1R)-2,6-anhydro-3,4,5,7-tetra-O-benzyl-D-glycero-L-manno-heptitol-1-C-yl]-2,3-dideoxy-β-D-lyxo-hexopyranose-1',4-acetonide 13

A mixture of **12** (47 mg, 0.07 mmol), 2,2-dimethoxypropane (1.3 mL), dry acetone (1.3 mL) and PPTS (13 mg) was stirred at 20°C for 2 h. After the addition of CH₂Cl₂ (10 mL) and H₂O (20 mL), the aqueous phase was extracted with CH₂Cl₂ (3 × 10 mL). The combined organic extracts were washed with a satd aq soln of NaHCO₃ (20 mL), brine (20 mL) and dried over MgSO₄. Solvent evaporation, FC (8:2 light petroleum ether/EtOAc) afforded 31 mg (62%) of **13**, colorless oil. $[\alpha]_{589}^{25} = +1$, $[\alpha]_{546}^{25} = +3$, $[\alpha]_{435}^{25} = +5$, $[\alpha]_{405}^{25} = +8$ (c 0.24, CHCl₃). UV (MeCN) 212 (15400). IR (film) 3030, 2865, 1495, 1455, 1365, 1210, 1135, 1100, 1030, 910, 735, 695 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.34–7.26 (m, 20H, ArH), 5.48 (d, ³J_{1,2_{exo}} = 4.0, H-1), 5.03–4.44 (m, 8H, 4OCH₂Ph), 4.51 (br dd, ³J_{4,5} = 6.4, ³J_{5,6_{exo}} = 5.7, H-5), 4.43 (br dd, ³J_{3,4} = 8.2, ³J_{4,5} = 6.4, H-4), 4.29 (d, ²J = 7.7, H_{endo}-6), 4.14 (dd, ³J_{3',4'} = 9.4, ³J_{2',3'} = 9.4, H-3'), 4.11 (dd, ³J_{1',3} = 11.2, ³J_{1',2'} = 2.1, H-1'), 3.97 (d, ³J_{4',5'} = 2.2, H-5'), 3.63–3.57 (m, 4H, H-4', H_{exo}-6, H₂-7'), 3.26 (m, H-6'), 3.25 (dd, ³J_{2',3'} = 9.4, ³J_{1',2'} = 2.1, H-2'), 2.58 (dddd, ³J_{1',3} = 11.2, ³J_{2_{exo},3} = 9.6, ³J_{3,4} = 8.2, ³J_{2_{endo},3} = 5.0, H-3), 1.90 (ddd, ²J = 14.8, ³J_{2_{exo},3} = 9.6, ³J_{1,2_{exo}} = 4.0, H_{exo}-2), 1.44 (dd, ²J = 14.8, ³J_{2_{endo},3} = 5.0, H_{endo}-2), 1.41 (s, 3H, H_b-3), 1.31 (s, 3H, H_a-3). ¹³C NMR (100.6 MHz, CDCl₃) δ 138.9, 138.9, 138.3, 138.0 (4s, 4C_{arom}), 128.4–127.3 (20d, CH_{arom}), 100.6 (s, C_{acetonide}), 99.9 (d, 170, C-1), 85.5 (d, 137, C-4'), 77.7, 77.7 (2d, 140, 140, C-2', C-6'), 74.8 (t, 145, OCH₂Ph), 74.2 (d, 147, C-3'), 74.1 (t, 146, OCH₂Ph), 73.6 (d, 150, C-5'), 73.5 (t, 141, OCH₂Ph), 72.2 (t, 141, OCH₂Ph), 72.0 (d, 155, C-5), 69.8 (d, 145, C-1'), 69.1 (t, 145, C-7'), 65.2 (d, 148, C-4), 62.9 (t, 150, C-6), 30.7 (t, 127, C-2), 28.4 (d, 134, C-3), 27.5 (q, 129, Me(b)acetonide), 25.5 (q, 126, Me(a)acetonide). CI-MS (NH₃) *m/z* 741 (28, [M+18]⁺), 573 (7), 181 (7), 91 (100). Anal. Calcd for C₄₄H₅₀O₉: C, 73.11; H, 6.97. Found: C, 73.09; H, 7.04.

4.6. 4-*O*-Acetyl-1,6-anhydro-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- β -*D*-lyxo-hexopyranose **14**

Metallic Na (530 mg, 23 mmol) was added to liquid NH₃ (30 mL, condensed at -78°C). A solution of **12** (642 mg, 0.94 mmol) in anhydrous THF (8 mL) was added dropwise under stirring. After stirring at -78°C for 40 min, solid NH₄Cl (1.3 g) was added and the cooling bath removed. Once at 20°C , the residue was taken in MeOH and purified by FC (2:1 CH₂Cl₂/MeOH) affording an oil that was mixed with Ac₂O (6 mL), pyridine (9 mL), 4-dimethylaminopyridine (0.5 mg) and stirred at 20°C for 15 h. Solvent evaporation in vacuo gave a residue, which was taken in toluene (10 mL) and the solvent evaporated to dryness in vacuo. The latter operation was repeated and the residue purified by FC (1:1 light petroleum ether/EtOAc) affording 475 mg (88%, two steps), white solid, mp $84-86^{\circ}\text{C}$. $[\alpha]_{589}^{25} = +24$, $[\alpha]_{546}^{25} = +28$, $[\alpha]_{435}^{25} = +46$, $[\alpha]_{405}^{25} = +57$ (c 0.28, CHCl₃). UV (MeCN) final absorbance: 194 ($\epsilon = 1500$). IR (KBr) 3470, 2975, 1750, 1375, 1245, 1120, 1085, 1050, 1030, 945, 910, 595 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 5.58 (d, ³ $J_{1,2\text{endo}} = 5.7$, H-1), 5.41 (d, ³ $J_{4',5'} = 3.4$, H-5'), 5.27 (dd, ³ $J_{1',3} = 10.6$, ³ $J_{1',2'} = 2.2$, H-1'), 5.14 (dd, ³ $J_{3',4'} = 10.0$, ³ $J_{2',3'} = 9.9$, H-3'), 5.11 (m, H-4), 5.01 (dd, ³ $J_{3',4'} = 10.0$, ³ $J_{4',5'} = 3.4$, H-4'), 4.80 (dd, ³ $J_{4,5} = 7.8$, ³ $J_{5,6\text{exo}} = 4.7$, H-5), 4.21 (dd, ² $J = 11.4$, ³ $J_{6',7'a} = 7.5$, H_a-7'), 4.08 (dd, ² $J = 11.4$, ³ $J_{6',7'b} = 5.7$, H_b-7'), 3.85 (m, H-6'), 3.84 (d, ² $J = 7.7$, H_{endo}-6), 3.52 (dd, ³ $J_{2',3'} = 9.9$, ³ $J_{1',2'} = 2.2$, H-2'), 3.43 (dd, ² $J = 7.7$, ³ $J_{5,6\text{exo}} = 4.7$, H_{exo}-6), 2.49 (dddd, ³ $J_{2,3\text{endo}} = 11.7$, ³ $J_{1',3} = 10.6$, ³ $J = 6.5$, ³ $J = 5.2$, H-3), 2.18–1.97 (19H, H_{exo}-2, 6 MeCOO), 1.53 (dd, ² $J = 13.2$, ³ $J_{2\text{endo},3} = 11.7$, H_{endo}-2). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.8, 170.2, 170.1, 170.0, 169.6, 169.5 (6s, -COO), 98.3 (d, 174, C-1), 76.9 (d, 142, C-2'), 75.3 (d, 141, C-6'), 72.6 (d, 148, C-4'), 72.2 (d, 158, C-5), 68.4 (d, 154, C-4), 68.0 (d, 149, C-1'), 67.4 (d, 153, C-5'), 64.6 (d, 156, C-3'), 62.7 (t, 152, C-6), 61.6 (t, 149, C-7'), 30.9 (t, 129, C-2), 30.5 (d, 133, C-3), 20.7–20.5 (6q, 130, CH₃COO). CI-MS (NH₃) m/z 592 (100, [M+18]⁺), 515 (35). Anal. Calcd for C₂₅H₃₄O₁₅: C, 52.26; H, 5.96. Found: C, 52.19; H, 6.00.

4.7. 1,4,6-Tri-*O*-acetyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- α -*D*-lyxo-hexopyranose **15 α , β**

A mixture of **14** (445 mg, 0.77 mmol), Ac₂O (16 mL) and CF₃COOH (3.8 mL) was stirred at 20°C for 4 h. This was poured onto ice (20 mL) and neutralized with a satd aq soln of NaHCO₃ (pH 8). The mixture was extracted with EtOAc (3 $\times$ 30 mL). The combined organic extracts were washed with brine (50 mL) and dried over MgSO₄. Solvent evaporation, FC (1:2 light petroleum ether/EtOAc) afforded 422 mg (81%) of a colorless oil, a 1:0.3 mixture of **15 α** /**15 β** . $[\alpha]_{589}^{25} = +51$, $[\alpha]_{546}^{25} = +59$, $[\alpha]_{435}^{25} = +98$, $[\alpha]_{405}^{25} = +118$ (c 0.26, CHCl₃). UV (MeCN) final absorbance: 194 ($\epsilon = 1800$). IR (film) 2970, 1750, 1435, 1370, 1235, 1115, 1055, 940, 755 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) data for the anomer **15 α** : δ 6.27 (d, ³ $J_{1,2\text{ax}} = 1.8$, H-1), 5.44 (d,

³ $J_{4',5'} = 3.1$, H-5'), 5.17 (dd, ³ $J_{3',4'} = 9.9$, ³ $J_{2',3'} = 9.9$, H-3'), 5.15–4.97 (m, 3H, H-1', H-4, H-4'), 4.26–3.80 (m, 6H, H-5, H-6', H₂-6, H₂-7'), 3.59 (dd, ³ $J_{2',3'} = 9.9$, ³ $J_{1',2'} = 2.4$, H-2'), 2.79 (m, H-3), 2.17–1.97 (25H, H_{ax}-2, 8 MeCOO), 1.69 (dd, ² $J = 13.0$, ³ $J_{2\text{eq},3} = 3.3$, H_{eq}-2). For the anomer **15 β** : δ 5.76 (dd, ³ $J_{1,2\text{ax}} = 9.8$, ³ $J_{1,2\text{eq}} = 2.5$, H-1), 5.41 (d, ³ $J_{4',5'} = 3.2$, H-5'), 2.58 (m, H-3). ¹³C NMR (100.6 MHz, CDCl₃) data for the anomer **15 α** : δ 170.5–168.8 (8s, -COO), 91.1 (d, 174, C-1), 76.2 (d, 138, C-2'), 75.1 (d, 141, C-6'), 72.6 (d, 148, C-4'), 70.5 (d, 144, C-5), 67.8, 64.1 (2d, 147, 157, C-1', C-4), 67.1 (d, 154, C-5'), 64.5 (d, 156, C-3'), 63.2, 60.7 (2t, 150, 153, C-6, C-7'), 33.3 (d, 134, C-3), 26.0 (t, 130, C-2), 20.9–20.5 (8q, 130, CH₃COO). For the anomer **15 β** : δ 93.1 (d, 165, C-1), 37.9 (d, 128, C-3), 27.5 (t, 130, C-2). CI-MS (NH₃) m/z 695 (76, [M+18]⁺), 634 (65), 617 (100), 556 (10), 496 (20). Anal. Calcd for C₂₉H₄₀O₁₈: C, 51.48; H, 5.96. Found: C, 51.47; H, 6.08.

4.8. 4,6-Di-*O*-acetyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-3-deoxy-*D*-galactal **3a**

A mixture of **15 α , β** (354 mg, 0.52 mmol) and silica gel (1.2 g) in toluene (13 mL) was heated under reflux for 6 h in a flask equipped with a Dean–Stark apparatus. After cooling to 20°C and evaporation of the solvent, a FC (1:1 light petroleum ether/EtOAc) afforded 263 mg (82%) of **3a**, white solid, mp $83-85^{\circ}\text{C}$. $[\alpha]_{589}^{25} = +17$, $[\alpha]_{546}^{25} = +21$, $[\alpha]_{435}^{25} = +30$, $[\alpha]_{405}^{25} = +32$ (c 0.25, CHCl₃). UV (MeCN) final absorbance: 204 ($\epsilon = 8800$). IR (KBr) 1750, 1650, 1435, 1370, 1240, 1055 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 6.51 (dd, ³ $J_{1,2} = 6.3$, ⁴ $J_{1,3} = 2.5$, H-1), 5.43 (d, ³ $J_{4',5'} = 3.3$, H-5'), 5.29 (d, ³ $J_{3,4} = 3.1$, H-4), 5.13 (dd, ³ $J_{3',4'} = 9.6$, ³ $J_{2',3'} = 9.6$, H-3'), 5.12 (m, H-1'), 5.03 (dd, ³ $J_{3',4'} = 9.6$, ³ $J_{4',5'} = 3.3$, H-4'), 4.49 (br d, ³ $J_{1,2} = 6.3$, H-2), 4.24–4.07 (m, 4H, H-5, H_a-6, H₂-7'), 3.99 (dd, ² $J = 10.3$, ³ $J_{5,6b} = 6.2$, H_b-6), 3.89 (dd, ³ $J_{6',7'a} = 7.0$, ³ $J_{6',7'b} = 6.2$, H-6'), 3.71 (dd, ³ $J_{2',3'} = 9.6$, ³ $J_{1',2'} = 2.4$, H-2'), 3.19 (br d, ³ $J_{1',3} = 10.7$, H-3), 2.18, 2.08, 2.06, 2.05, 2.04, 1.99, 1.97 (7s, 21H, 7 MeCOO). ¹³C NMR (100.6 MHz, CDCl₃) δ 171.0–169.5 (7s, -COO), 145.0 (d, 190, C-1), 96.5 (d, 165, C-2), 76.4 (d, 146, C-2'), 75.4 (d, 143, C-6'), 74.7 (d, 146, C-5), 72.8 (d, 148, C-4'), 67.7, 64.7 (2d, 150, 155, C-1', C-3'), 67.5 (d, 153, C-5'), 63.4 (t, 148, C-6), 63.2 (d, 152, C-4), 62.5 (t, 150, C-7'), 36.0 (d, 130, C-3), 20.9–20.5 (7q, 130, 7 MeCOO). CI-MS (NH₃) m/z 634 (100, [M+18]⁺), 617 (43, [M+1]⁺), 557 (18), 496 (34). Anal. Calcd for C₂₇H₃₆O₁₆: C, 52.60; H, 5.89. Found: C, 52.53; H, 5.92.

4.9. 4,6-Di-*O*-benzyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-benzyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-3-deoxy-*D*-galactal **3b**

To a solution of **3a** (850 mg, 1.37 mmol) in MeOH (35 mL) was added Na₂CO₃ (830 mg, 7.8 mmol). The reaction mixture was stirred at 20°C for 1.5 h, filtrated, and the solvent evaporated. The crude polyol dissolved in anhyd DMF (12 mL) was added dropwise at 0°C to a suspension of NaH (0.7 g, 15 mmol, 55% dispersion in paraffin) in DMF (5 mL). After 20 min, benzyl bro-

mid (1.5 mL, 13 mmol) in DMF (2.5 mL) and tetrabutylammonium iodide (30 mg) were added. The reaction mixture was brought to 20 °C and stirred for 15 h. After completion of the reaction, the mixture was cooled to 0 °C, quenched with H₂O (50 mL) and extracted with Et₂O (3 × 50 mL). The combined organic phases were washed with brine (3 × 50 mL) and dried over MgSO₄. Solvent evaporation, FC (9:1 then 8.5:1.5 light petroleum/EtOAc) afforded 994 mg (76%, 2 steps) of **3b**, colorless oil. $[\alpha]_{589}^{25} = -2.0$, $[\alpha]_{546}^{25} = -3.5$, $[\alpha]_{435}^{25} = -12$, $[\alpha]_{405}^{25} = -19$ (c 0.26, CHCl₃). UV (MeCN) 258 (2000), 217 (16700). IR (film) 3065, 3030, 2865, 1650, 1495, 1455, 1360, 1250, 1095, 735, 695 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.30–7.02 (m, 35H, ArH), 6.39 (dd, ³J_{1,2} = 6.2, ⁴J_{1,3} = 2.5, H-1), 4.97–4.31 (m, 14H, 7 OCH₂Ph), 4.45 (d, ³J_{1,2} = 6.2, H-2), 4.29 (dd, ³J_{1',3} = 10.3, ³J_{1',2'} = 2.3, H-1'), 4.22 (dd, ³J_{3',4'} = 9.5, ³J_{2',3'} = 9.5, H-3'), 4.04 (br t, ³J_{5,6a} = 6.4, ³J_{5,6b} = 6.4, H-5), 4.00 (d, ³J = 2.2, H-5'), 3.96 (br s, H-4), 3.67–3.50 (m, 6H, H-4', H₂-7', H-2', H_a-6, H-6'), 3.38 (dd, ²J = 9.5, ³J_{5,6b} = 6.4, H_b-6), 3.26 (br d, ³J_{1',3} = 10.3, H-3). ¹³C NMR (100.6 MHz, CDCl₃) δ 144.1 (d, 188, C-1), 139.2, 139.0, 138.6, 138.5, 138.4, 137.9, 137.9 (7s, 7C_{arom}), 128.4–127.0 (35d, CH_{arom}), 98.3 (d, 162, C-2), 84.8 (d, 138, C-4'), 79.1 (d, 138, C-2'), 77.2 (d, 141, C-6'), 76.9 (d, 144, C-5), 75.2 (d, 147, C-3'), 75.2 (t, 144, OCH₂Ph), 74.6 (t, 139, OCH₂Ph), 74.3 (t, 144, OCH₂Ph), 74.1 (d, 143, C-5'), 73.5 (t, 137, OCH₂Ph), 73.5 (d, 147, C-1'), 73.3 (t, 141, OCH₂Ph), 72.3 (t, 137, OCH₂Ph), 70.4 (d, 145, C-4), 69.5 (t, 142, C-6), 69.0 (t, 143, C-7'), 67.1 (t, 143, OCH₂Ph), 35.0 (d, 127, C-3). CI-MS (NH₃) *m/z* 971 (3, [M+18]⁺), 861 (5), 723 (7), 616 (4), 445 (3), 181 (7), 91 (100). Anal. Calcd for C₆₂H₆₄O₉: C, 78.13; H, 6.77. Found: C, 78.15; H, 6.84.

4.10. Methyl 2,4,6-tri-*O*-benzyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-benzyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-3-deoxy-*β*-*D*-galacto-pyranoside 2

Galactal **3a** (90 mg, 0.09 mmol) was dissolved in 1.8 mL of CH₂Cl₂, and the resulting solution was cooled to 0 °C. A solution of dimethyldioxirane (~0.05 M in acetone, 3.5 mL, 0.17 mmol) was added dropwise. The reaction mixture was stirred at 0 °C for 1 h, until TLC indicated complete consumption of the glycal. The solution was evaporated with a stream of dry N₂ and the residue dried in vacuo to afford the 1,2-anhydro sugar. The 1,2-anhydro sugar was dissolved in 2.0 mL of anhydrous MeOH, and 300 μL of CH₂Cl₂ and the solution stirred at 20 °C for 4.5 h. The MeOH was removed in vacuo to afford methyl glycoside **17**. A part of the crude methyl glycoside (33 mg, 0.03 mmol) dissolved in anhydrous DMF (0.3 mL) was added dropwise at 0 °C to a suspension of NaH (9 mg, 0.2 mmol, 55% dispersion in paraffin) in DMF (0.2 mL). After 20 min, benzyl bromide (16 μL, 0.14 mmol) in DMF (0.1 mL) and tetrabutylammonium iodide (2 mg) were added. The reaction mixture was brought to 20 °C and stirred for 15 h. After completion of the reaction, the mixture was cooled to 0 °C, quenched with H₂O (10 mL), and extracted with Et₂O (3 × 10 mL). The combined organic phases were washed with brine (3 × 10 mL) and dried over MgSO₄. Solvent evaporation, FC (8:2 light petroleum/EtOAc) afforded

26 mg (71%, 3 steps) of **2**, colorless oil. $[\alpha]_{589}^{25} = +24$, $[\alpha]_{546}^{25} = +28$, $[\alpha]_{435}^{25} = +51$, $[\alpha]_{405}^{25} = +60$ (c 0.25, CHCl₃). UV (MeCN) 254 (2000), 216 (22000). IR (film) 3090, 3065, 3030, 2920, 2860, 1495, 1455, 1360, 1210, 1095, 990, 735, 695 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.37–7.08 (m, 40H, ArH), 5.00–4.32 (m, 16H, 8OCH₂Ph), 4.42 (m, H-1'), 4.32 (d, ³J_{1,2} = 9.5, H-1), 4.21 (dd, ³J_{3',4'} = 9.5, ³J_{2',3'} = 9.5, H-3'), 4.09 (d, ³J_{3,4} = 1.8, H-4), 3.89 (d, ³J_{4',5'} = 2.3, H-5'), 3.71–3.67 (m, 2H, H-2, H-5'), 3.66 (dd, ³J_{2',3'} = 9.5, ³J_{1',2'} = 2.1, H-2'), 3.59–3.57 (m, 3H, H₂-6, H_a-7'), 3.53 (s, 3H, OCH₃), 3.52 (m, H_b-7'), 3.42 (dd, ³J_{3',4'} = 9.5, ³J_{4',5'} = 2.3, H-4'), 3.08 (dd, ³J_{6',7'a} = 7.4, ³J_{6',7'b} = 5.8, H-6'), 2.41 (dt, ³J_{2,3} = 9.5, ³J_{1',3} = 9.5, ³J_{3,4} = 1.8, H-3). ¹³C NMR (100.6 MHz, CDCl₃) δ 139.2, 139.2, 139.1, 138.8, 138.8, 138.5, 138.2, 138.1 (8s, 8C_{arom}), 128.4–126.8 (40d, CH_{arom}), 106.8 (d, 161, C-1), 84.9 (d, 135, C-4'), 81.1 (d, 141, C-2'), 77.2 (d, C-2), 76.6 (d, C-5), 76.1 (d, C-6'), 75.8 (d, C-3'), 74.9, 74.4, 74.2 (3t, 3 OCH₂Ph), 74.1, 74.05, 73.9 (3d, C-1', C-4, C-5'), 74.0, 73.3, 73.2, 71.9, 69.7 (5t, 5 OCH₂Ph), 69.2 (t, C-6), 68.9 (t, C-7'), 56.8 (q, 142, OCH₃), 44.5 (d, 122, C-3). Electrospray-MS (+, 50:50:1 MeCN/H₂O/AcOH) *m/z* 1113.8 (17, [M+Na]⁺), 1108.3 (53, [M+18]⁺), 1059.4 (35).

4.11. Methyl 4,6-di-*O*-benzyl-1,3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-benzyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-3-deoxy-*α*-*D*-talo-pyranoside 16

Galactal **3b** (104 mg, 0.11 mmol) was dissolved in anhydrous MeOH (1 mL) and CH₂Cl₂ (30 μL) and the resulting solution cooled to 0 °C. *m*CPBA (32 mg, 0.13 mmol) was added and the reaction mixture stirred at 0 °C for 1.5 h, until TLC indicated complete consumption of the glycal. After the addition of CH₂Cl₂ (15 mL), H₂O (10 mL), and NaHCO₃ (10 mL), the aqueous phase was extracted with CH₂Cl₂ (15 mL, three times). The combined organic extracts were washed with brine (20 mL) and dried over MgSO₄. Solvent evaporation afforded a mixture of methyl glycosides. The major product **16** (52%) being the one for which epoxidation occurred on the β face was contaminated with a mixture of **17** (mixture of anomers) (20%) for which epoxidation occurred on the α face. FC (7.5:2.5 light petroleum/EtOAc) afforded 55 mg (52%) of pure **16**, colorless oil. $[\alpha]_{589}^{25} = +29$, $[\alpha]_{546}^{25} = +40$, $[\alpha]_{435}^{25} = +65$, $[\alpha]_{405}^{25} = +79$ (c 0.11, CHCl₃). UV (MeCN) 251 (2300), 215 (25400). IR (film) 3500, 3030, 2910, 2865, 1495, 1455, 1360, 1210, 1095, 1060, 910, 735, 695 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.36–7.11 (m, 35H, ArH), 5.05–4.73 (m, 7H, OCH₂Ph), 4.69 (s, H-1), 4.68 (dd, ³J_{1',3} = 11.1, ³J_{1',2'} = 2.6, H-1'), 4.60–4.45 (m, 7H, OCH₂Ph), 4.30 (dd, ³J_{3',4'} = 9.5, ³J_{2',3'} = 9.6, H-3'), 4.05–4.02 (m, 3H, H-5', H-5, H-4), 3.77 (dd, ³J_{2',3'} = 9.6, ³J_{1',2'} = 2.6, H-2'), 3.74–3.58 (m, 7H, H-4', H-2, H-6', H₂-6, H₂-7'), 3.33 (s, 3H, OCH₃), 2.82 (dt, ³J_{1',3} = 11.1, ³J_{2,3} = 2.0, ³J_{3,4} = 2.0, H-3). ¹³C NMR (100.6 MHz, CDCl₃) δ 139.2, 139.0, 138.9, 138.4, 138.1, 138.0, 137.7 (7s, 7C_{arom}), 128.4–127.0 (35d, CH_{arom}), 101.7 (d, 169, C-1), 84.9 (d, 139, C-4'), 78.6 (d, 141, C-2'), 77.4 (d, 144, C-6'), 75.3 (t, 143, OCH₂Ph), 75.2 (d, 141, C-3'), 74.9 (t, 142, OCH₂Ph), 74.6 (t, 141, OCH₂Ph), 74.5 (d, 142,

C-5'), 73.5, 69.9 (2d, 145, 147, C-4, C-5), 73.4 (t, 141, OCH₂Ph), 73.3 (t, 139, OCH₂Ph), 72.4 (t, 144, OCH₂Ph), 71.2 (d, 143, C-1'), 69.3, 69.2 (2t, 143, 143, C-6, C-7'), 67.9 (d, 149, C-2), 66.9 (t, 146, OCH₂Ph), 54.9 (q, 139, OCH₃), 35.0 (d, 125, C-3). CI-MS (NH₃) *m/z* 1018 (1, [M+17]⁺), 909 (1), 723 (1), 181 (7), 91 (100).

4.12. *N*-[(Benzyloxy)carbonyl]-*O*-{4,6-di-*O*-acetyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy-2-iodo- α -*D*-talo-pyranosyl]-*L*-serine phenylmethyl ester 18

A solution of galactal **3a** (44 mg, 0.071 mmol) and *Z*-Ser-OBn (30 mg, 0.091 mmol) in CH₂Cl₂ (2 mL) was stirred for 30 min at 20 °C in the presence of powdered 4 Å molecular sieves (20 mg). I(sym-collidine)₂ClO₄ (176 mg, 0.375 mmol) was added, the reaction stirred for 2 h at 20 °C and then filtered. The filtrate was washed with 10% aq soln of Na₂S₂O₃ (5 mL), brine (10 mL), and dried over MgSO₄. Solvent evaporation, FC (6:4 light petroleum/EtOAc) afforded 55 mg (72%) of **18**, colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.43–7.32 (m, 10H, ArH), 5.91 (d, ³J_{N,C*} = 7.9, H-N), 5.36 (dd, ³J_{4',5'} = 2.2, ³J_{5',6'} = 0.9, H-5'), 5.31–5.08 (m, 4H, 2 OCH₂Ph), 5.25 (dd, ³J_{1',3} = 10.2, ³J_{1',2'} = 2.3, H-1'), 5.20 (s, H-1), 5.07 (dd, ³J_{3',4'} = 9.6, ³J_{2',3'} = 9.6, H-3'), 5.01 (dd, ³J_{3',4'} = 9.6, ³J_{4',5'} = 2.2, H-4'), 5.00 (m, H-4), 4.59 (dt, ³J_{C*,N} = 7.9, ³J_{C*,H2-Ser} = 2.8, H-C*), 4.19 (dd, ²J = 11.2, ³J_{6',7a} = 8.7, H_a-7'), 4.12 (dd, ²J = 11.5, ³J_{5,6a} = 3.3, H_a-6), 4.02–3.96 (m, 4H, H-5, H_b-7', H₂-Ser), 3.87 (dd, ²J = 11.5, ³J_{5,6b} = 8.3, H_b-6), 3.67 (d, ³J_{2,3} = 3.7, H-2), 3.57–3.53 (m, 2H, H-2', H-6'), 2.39 (ddd, ³J_{1',3} = 10.2, ³J_{2,3} = 3.7, ³J_{3,4} = 3.0, H-3), 2.15–1.97 (7s, 21H, 7 MeCOO). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.6, 170.5, 170.2, 170.2, 170.1, 170.1, 169.6, 169.4 (8s, -COO), 155.7 (s, HN-COO), 136.1, 135.5 (2s, 2C_{arom}), 128.7–128.1 (10d, CH_{arom}), 102.0 (d, C-1), 75.3, 74.8 (2d, C-2', C-6'), 72.6 (d, C-4'), 69.8 (d, C-1'), 68.3 (d, C-5), 68.2 (t, CH₂-Ser), 67.2, 67.1 (2t, 2OCH₂Ph), 67.0 (d, C-5'), 64.4 (d, C-3'), 63.0 (t, C-6), 62.5 (d, C-4), 60.1 (t, C-7'), 54.3 (d, C*), 35.3 (d, C-3), 20.8–20.3 (7q, 1d, CH₃COO, C-2). Electrospray-MS (+, 50:50:1 MeCN/H₂O/AcOH) *m/z* 1089.5 (40, [M+18]⁺), 1072.1 (100, [M]⁺), 743.4 (15).

4.13. *N*-[(9*H*-Fluoren-9-ylmethoxy)carbonyl]-*O*-{4,6-di-*O*-acetyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy-2-iodo- α -*D*-talo-pyranosyl]-*L*-serine phenylmethyl ester 19

A solution of galactal **3a** (94 mg, 0.15 mmol) and Fmoc-Ser-OBn (81 mg, 0.19 mmol) in CH₂Cl₂ (4.3 mL) was stirred for 30 min at 20 °C in the presence of powdered 4 Å molecular sieves (30 mg). I(sym-collidine)₂ClO₄ (350 mg, 0.75 mmol) was added, the reaction stirred 2 h at 20 °C and then filtered. The filtrate was washed with a 10% aq soln of Na₂S₂O₃ (10 mL), brine (20 mL) and dried over MgSO₄. Solvent evaporation, FC (5:5 light petroleum/EtOAc) afforded 120 mg (70%) of **19**, white solid, mp 87–90 °C. [α]₅₈₉²⁵ = +45, [α]₅₄₆²⁵ = +54, [α]₄₃₅²⁵ = +92, [α]₄₀₅²⁵ = +109 (*c* 0.19, CHCl₃). UV (MeCN) 299 (7500), 288 (6600), 265 (22400), 209 (49200). IR (KBr) 3400, 2965, 1750, 1520, 1370, 1235, 1055, 740,

595 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.79–7.31 (m, 13H, ArH), 6.05 (d, ³J_{N,C*} = 7.7, H-N), 5.38 (dd, ³J_{4',5'} = 3.2, ³J_{5',6'} = 1.0, H-5'), 5.32–5.16 (m, 2H, OCH₂Ph), 5.27 (dd, ³J_{1',3} = 12.0, ³J_{1',2'} = 1.9, H-1'), 5.23 (s, H-1), 5.10 (dd, ³J_{3',4'} = 9.7, ³J_{2',3'} = 9.7, H-3'), 5.03 (dd, ³J_{3',4'} = 9.7, ³J_{4',5'} = 3.2, H-4'), 5.02 (d, ³J_{3,4} = 2.8, H-4), 4.61 (dt, ³J_{C*,N} = 7.7, ³J_{C*,H2-Ser} = 2.8, H-C*), 4.41–4.38 (m, 2H, H₂-Fmoc), 4.26–4.23 (m, 2H, H-Fmoc), H_a-7', 4.10–3.95 (m, 5H, H_a-6, H_b-7', H₂-Ser, H-5), 3.88 (dd, ²J = 11.4, ³J_{5,6b} = 8.2, H_b-6), 3.68 (d, ³J_{2,3} = 3.9, H-2), 3.56 (dd, ³J_{2',3'} = 9.7, ³J_{1',2'} = 1.9, H-2'), 3.55 (m, H-6'), 2.44 (ddd, ³J_{1',3} = 12.0, ³J_{2,3} = 3.9, ³J_{3,4} = 2.8, H-3), 2.15, 2.07, 2.06, 2.03, 1.99, 1.98, 1.97 (7s, 21H, 7 MeCOO). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.6–169.4 (8s, -COO), 155.8 (s, HN-COO), 143.8, 143.8, 141.3, 141.3, 135.4 (5s, 5C_{arom}), 128.7–120.0 (13d, CH_{arom}), 102.2 (d, 175, C-1), 75.3 (d, 140, C-2'), 74.9 (d, 141, C-6'), 72.6 (d, 148, C-4'), 69.9 (d, 152, C-1'), 68.4 (d, 146, C-5), 68.4 (t, 148, CH₂-Ser), 67.3, 67.3 (2t, 149, OCH₂Ph, CH₂-Fmoc), 67.1 (d, 152, C-5'), 64.5 (d, 155, C-3'), 63.0 (t, 150, C-6), 62.5 (d, 150, C-4), 60.2 (t, 149, C-7'), 54.4 (d, 140, C*), 47.0 (d, 133, CH-Fmoc), 35.4 (d, 128, C-3), 20.8–20.4 (7q, 1d, 130, CH₃COO, C-2). Electrospray-MS (+, 50:50:1 MeCN/H₂O/AcOH) *m/z* 1182 (20, [M+Na]⁺), 1159 (100, [M]⁺). Anal. Calcd for C₅₂H₅₈O₂₁NI: C, 53.85; H, 5.04. Found: C, 53.93; H, 5.02.

4.14. *N*-[(Benzyloxy)carbonyl]-*O*-{4,6-di-*O*-acetyl-3-*C*-[(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- α -*D*-threo-hex-2-enopyranosyl]-*L*-serine phenylmethyl ester 20

Glycoconjugate **18** (7.5 mg, 0.007 mmol) was dissolved in DMF_{*d*7} (350 μ L, reaction followed by ¹H NMR) and NaN₃ (1.6 mg, 0.025 mmol) then added. After 16 h at 20 °C, only one product formed cleanly (by ¹H NMR). Evaporation and FC (5:5 light petroleum/EtOAc) afforded 7 mg (90%) of **20**, white solid, mp 52–55 °C. [α]₅₈₉²⁵ = -42, [α]₅₄₆²⁵ = -43, [α]₄₃₅²⁵ = -81, [α]₄₀₅²⁵ = -104 (*c* 0.094, CHCl₃). UV (MeCN) 262 (9000), 197 (17200). IR (KBr) 2975, 1750, 1370, 1230, 1050, 700 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.30 (m, 10H, ArH), 5.84 (d, ³J_{N,C*} = 8.8, H-N), 5.80 (d, ³J_{1,2} = 2.4, H-2), 5.45 (d, ³J_{4,5} = 1.1, H-4), 5.41 (d, ³J_{4',5'} = 3.0, H-5'), 5.30–5.25 (m, 2H, H-1', H-3'), 5.24–5.12 (m, 4H, OCH₂Ph), 5.02–4.99 (m, 2H, H-1, H-4'), 4.60 (dt, ³J_{C*,N} = 8.8, ³J_{C*,H2-Ser} = 2.8, H-C*), 4.18–3.95 (m, 7H, H-5, H₂-7', H₂-Ser, H₂-6), 3.76 (br t, ³J_{6',H2-7'} = 6.3, H-6'), 3.43 (dd, ³J_{2',3'} = 9.8, ³J_{1',2'} = 2.3, H-2'), 2.19, 2.09, 2.08, 2.03, 1.99, 1.99, 1.97 (7s, 21H, 7 MeCOO). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.5, 170.3, 170.2, 170.1, 169.9, 169.9, 169.8, 169.5 (8s, -COO), 155.9 (s, HN-COO), 136.0, 135.3, 133.8 (3s, 2C_{arom}, C-3), 128.6–128.1 (11d, 10CH_{arom}, C-2), 94.8 (d, 169, C-1), 79.2 (d, 144, C-2'), 75.1 (d, 143, C-6'), 72.1 (d, 146, C-4'), 69.5, 65.1 (2d, 150, 154, C-1', C-3'), 69.4 (t, 147, CH₂-Ser), 68.0 (d, 146, C-5), 67.4 (d, 153, C-5'), 67.3 (t, 145, OCH₂Ph), 67.1 (t, 148, OCH₂Ph), 63.0 (d, 149, C-4), 62.3 (t, 150, C-6), 61.6 (t, 147, C-7'), 54.5 (d, 140, C*), 20.7–20.5 (7q, 130, CH₃COO). CI-MS (NH₃) *m/z* 961 (62,

[M+18]⁺, 615 (90), 337 (100), 91 (92). Anal. Calcd for C₄₅H₅₃O₂₁N: C, 57.26; H, 5.66. Found: C, 57.27; H, 5.70.

4.15. *N*-[*(9H*-Fluoren-9-ylmethoxy)carbonyl]-*O*-[4,6-di-*O*-acetyl-3-*C*-(1*R*)-1,3,4,5,7-penta-*O*-acetyl-2,6-anhydro-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- α -*D*-lyxo-hexopyranosyl]-*L*-serine phenylmethyl ester **21**

To a solution of **19** (58 mg, 0.05 mmol) in dry benzene (250 μ L) under an argon atmosphere was added Bu₃SnH (30 μ L, 0.113 mmol) and AIBN (3 mg). The solution was stirred for 45 min at 55 °C and then, concentrated in vacuo to afford a residue which was purified by FC (5:5 light petroleum/EtOAc) to provide 37 mg (72%) of **21**, white solid, mp 84–86 °C. [α]₅₈₉²⁵ = +31, [α]₅₄₆²⁵ = +39, [α]₄₃₅²⁵ = +64, [α]₄₀₅²⁵ = +76 (*c* 0.18, CHCl₃). UV (MeCN) 299 (8100), 288 (7000), 264 (24400), 211 (35700). IR (KBr) 3450, 2965, 1750, 1520, 1370, 1240, 1055, 805, 745, 595 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.79–7.30 (m, 13H, ArH), 6.04 (d, ³J_{N,C*} = 8.1, H-N), 5.38 (d, ³J_{4',5'} = 3.1, H-5'), 5.32–5.14 (m, 2H, OCH₂Ph), 5.16 (dd, ³J_{3',4'} = 9.8, ³J_{2',3'} = 9.8, H-3'), 4.98 (dd, ³J_{3',4'} = 9.8, ³J_{4',5'} = 3.1, H-4'), 4.96 (dd, ³J_{1',3} = 10.6, ³J_{1',2'} = 2.1, H-1'), 4.90 (s, H-4), 4.84 (d, ³J_{1,2ax} = 3.5, H-1), 4.61 (dt, ³J_{C*,N} = 8.1, ³J_{C*,H2-Ser} = 2.7, H-C*), 4.40–4.37 (m, 2H, H₂-Fmoc), 4.26–4.22 (m, 2H, H-Fmoc, H_a-7'), 4.14 (dd, ²J = 11.1, ³J_{6',7'b} = 5.3, H_b-7'), 4.05 (dd, ²J = 11.2, ³J_{5,6a} = 3.4, H_a-6), 3.98–3.92 (m, 3H, H₂-Ser, H-5), 3.85 (dd, ²J = 11.2, ³J_{5,6b} = 8.1, H_b-6), 3.63 (dd, ³J_{6',7'a} = 7.8, ³J_{6',7'b} = 5.3, H-6'), 3.45 (dd, ³J_{2',3'} = 9.8, ³J_{1',2'} = 2.1, H-2'), 2.73 (ddd, ³J_{2ax,3} = 12.8, ³J_{1',3} = 10.6, ³J_{2eq,3} = 3.6, H-3), 2.16, 2.06, 2.04, 2.00, 1.99, 1.98, 1.97 (7s, 21H, CH₃COO), 1.76 (ddd, ²J = 12.8, ³J_{2ax,3} = 12.8, ³J_{1,2ax} = 3.5, H_{ax}-2), 1.35 (dd, ²J = 12.8, ³J_{2eq,3} = 3.6, H_{eq}-2). ¹³C NMR (100.6 MHz, CDCl₃) δ 170.7–169.6 (8s, -COO), 155.8 (s, HN-COO), 143.8, 143.8, 141.2, 141.2, 135.5 (5s, 5C_{arom}), 128.6–120.0 (13d, CH_{arom}), 96.7 (d, 167, C-1), 76.3 (d, 144, C-2'), 74.9 (d, 141, C-6'), 72.7 (d, 148, C-4'), 68.8 (d, 148, C-5), 68.0 (d, 142, C-1'), 68.0 (t, 146, CH₂-Ser), 67.3 (t, 148, CH₂-Fmoc), 67.1 (d, 150, C-5'), 67.1 (t, 146, OCH₂Ph), 64.7 (d, 157, C-3'), 64.5 (d, 153, C-4), 63.6 (t, 147, C-6), 60.4 (t, 149, C-7'), 54.5 (d, 141, C*), 47.0 (d, 135, CH-Fmoc), 33.2 (d, 129, C-3), 27.0 (t, 131, C-2), 20.8–20.6 (7q, 130, CH₃COO). Electrospray-MS (+, 50:50:1 MeCN/H₂O/AcOH) *m/z* 1156.4 (18, [M+Na]⁺), 1034.3 (100, [M+1]⁺). Anal. Calcd for C₅₂H₅₉O₂₁N: C, 60.40, H, 5.75. Found: C, 60.42; H, 5.91.

4.16. 1,6-Anhydro-3-*C*-(1*R*)-2,6-anhydro-3,4,5,7-tetra-*O*-[(*tert*-butyl)dimethylsilyl]-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- β -*D*-glycero-hex-2-enopyran-4-ulose **6b**

A 1 M solution of Et₂AlI in toluene (12 mL, 12 mmol) was added dropwise to a mixture of **5b**¹⁵ (6 g, 9.40 mmol) and **4** (2 mg, 15.9 mmol) in CH₂Cl₂ (100 mL) at -78 °C. The solution was stirred at this temperature for 12 h and diluted with Et₂O (10 mL). Two molar aq HCl (0.5 mL) was added and the phases separated. The aqueous phase was extracted with Et₂O (2 $\times$ 10 mL). The combined organic phases were washed sequentially with 2 M aq

HCl (5 mL), H₂O (5 mL), and brine (5 mL), dried over MgSO₄, and concentrated in vacuo. FC (9:1, light petroleum ether/EtOAc) 6.9 g (95%), colorless oil.¹⁷ *R*_f = 0.38 (light petroleum ether/EtOAc). [α]₅₈₉²⁵ = +79, [α]₅₄₆²⁵ = +85, [α]₄₃₅²⁵ = +330, [α]₄₀₅²⁵ = +710 (*c* 0.24, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (dd, ³J_{1,2} = 3.5, ⁴J_{1',2} = 1.0, H-2), 5.83 (d, ³J_{1,2} = 3.5, H-1), 4.75 (dd, ³J_{5,6} = 6.4, ³J_{5,6} = 1.3, H-5), 4.45 (dd, ³J_{3',4'} = 8.6, ³J_{2',3'} = 7.0, H-3'), 4.26 (d, ²J = 12.4, H_a-7'), 4.23 (ddd, ³J_{1',2'} = 7.0, ³J_{1',OH} = 6.7, ⁴J_{1',2} = 1.0, H-1'), 4.06 (dd, ²J = 8.3, ³J_{5,6exo} = 6.4, H_{exo}-6), 3.99 (d, ³J_{3',4'} = 8.6, H-4'), 3.96 (d, ³J_{5',6'} = 4.1, H-5'), 3.91 (t, ³J_{1',2'} = ³J_{2',3'} = 7.0, H-2'), 3.80 (dd, ³J_{5',6'} = 4.1, ³J_{6',7'b} = 1.9, H-6'), 3.75 (dd, ²J = 12.4, ³J_{6',7'b} = 1.9, H_b-7'), 3.81 (dd, ²J = 10.2, ³J_{6',7'a} = 12.7, H_a-7'), 3.65 (dd, ²J = 8.3, ³J_{5,6endo} = 1.3, H_{endo}-6), 2.94 (d, ³J_{1',OH} = 6.7, OH), 0.94, 0.93, 0.90, 0.90 (4s, 36H, 4 *t*-Bu), 0.14, 0.12, 0.10, 0.09, 0.08, 0.07, 0.06, 0.05 (8s, 24H, 4Me₂Si). ¹³C NMR (100.6 MHz, CDCl₃) δ 194.5 (s, C-4), 143.5 (s, 165, C-2), 137.0 (s, C-3), 96.9 (d, 177, C-1), 79.7 (d, 141, C-2'), 79.1 (d, 160, C-5), 73.1 (d, 143, C-6'), 70.5 (d, 144, C-5'), 67.3 (d, 142, C-3'), 67.1 (d, 147, C-1'), 66.9 (d, 138, C-4'), 62.3 (t, 154, C-6), 58.2 (t, 142, C-7'), 25.9, 25.89, 25.85, 25.7 (4q, 125, (CH₃)₃CSi), 18.2, 18.1, 17.9, 17.0 (4s, (CH₃)₃CSi), -4.4, -4.6, -4.7, -4.9, -5.0, -5.1, -5.3, -5.5 (8q, 118, CH₃Si). CIMS HR *m/z* found 797.43190 (calcd for C₃₇H₇₄O₉Si₄ + Na: 797.4307). Anal. Calcd for C₃₇H₇₄O₉Si₄: C, 57.32; H, 9.62. Found: C, 57.24; H, 9.56.

4.17. 1,6-Anhydro-3-[(1*S*)-2,6-anhydro-3,4,5,7-tetra-*O*-[(*tert*-butyl)dimethylsilyl]-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- β -*D*-glycero-hexopyranos-4-ulose **22 and 1,6-anhydro-3-[(1*R*)-2,6-anhydro-3,4,5,7-tetra-*O*-[(*tert*-butyl)dimethylsilyl]-*D*-glycero-*L*-manno-heptitol-1-*C*-yl]-2,3-dideoxy- β -*D*-erythro-hexopyran-4-ulose **23****

One hundred and three milligrams of an aqueous suspension of Raney Nickel was added to a stirred solution of compound **10** (103 mg, 0.129 mmol) in tetrahydrofuran (1.11 mL) and the mixture was further stirred at 20 °C until complete conversion of the starting material (TLC control). The mixture diluted with Et₂O (200 mL) and filtrated through a pad of silica gel. FC (9.5:0.5, light petroleum ether/EtOAc), afforded 59 mg (57%) of **22** and 45 mg (43%) of **23**, both as colorless oil. Data of **22**: *R*_f = 0.16, (9.5:0.5, light petroleum ether/EtOAc). [α]₅₈₉²⁵ = +4, [α]₅₄₆²⁵ = +3, [α]₄₃₅²⁵ = -1, [α]₄₀₅²⁵ = -10 (*c* 0.42, CHCl₃). IR (film) 3405, 2955, 2860, 1715, 1460, 1360, 1265, 1095, 835, 775 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 6.12 (s, H-1), 4.50 (dd, ³J_{5',6'} = 2.2, ³J_{6',7'} = 9.7, H-6'), 4.42 (d, ³J_{5,6} = 5.4, H-5), 4.22 (dd, ³J_{6',7'} = 2.7, ²J = 11.8, H-7a'), 4.20 (dd, ³J_{3',4'} = 2.7, ³J_{2',3'} = 2.7, H-3), 4.0 (d, ²J = 8.9, H_{exo}-6), 3.85 (m, 3H, H_{endo}-6, H-4', H-1'), 3.75 (t, ³J_{2',3'} = 2.7, ³J_{1',2'} = 3.2, H-2'), 3.70 (dd, ³J_{6',7'} = 1.61, ²J = 11.8, H-7'), 3.55 (d, ³J_{5',6'} = 9.7, H-5'), 3.07 (m, H-3), 2.51 (m, H_{endo}-2), 2.13 (m, H_{exo}-2), 0.97, 0.97, 0.91, 0.88 (4s, 36H, 4 *t*-Bu), 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01 (8s, 24H, 4Me₂Si). ¹³C NMR (100.6 MHz, CDCl₃) δ 206.0 (s, C-4), 102.0 (d, 173, C-1), 79.5 (d, 141, C-2'), 79.5 (d, 163, C-5), 73.2 (d, 147, C-1'), 70.2 (d, 146, C-4'), 67.3 (d, 141, C-3'), 66.8 (t, 106, C-6), 65.2 (d,

146, C-6'), 64.7 (d, 140, C-5'), 58.5 (t, 145, C-7'), 44.4 (d, 125, C-3), 32.2 (t, 128, C-2, *t*-Bu), 18.4, 18.3, 18.1, 18.0 (4s, *t*-Bu), -4.4, -4.6, -4.8, -4.9, -5.0, -5.0, -5.3, -5.3, -5.5 (8q, 118, 4Me₂Si). CIMS HR *m/z* found 799.4464 (calcd for C₃₇H₇₆O₉Si₄ + Na: 799.4442).

Data of **23**: *R*_f = 0.16 (9.5:0.5, light petroleum ether/EtOAc). [α]₅₈₉²⁵ = +10, [α]₅₄₆²⁵ = +9, [α]₄₃₅²⁵ = +14, [α]₄₀₅²⁵ = +16 (c 0.44, CHCl₃). IR (film) 3405, 2955, 2860, 1715, 1460, 1360, 1265, 1095, 835, 775 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 6.12 (s, H-1), 4.50 (dd, ³*J*_{5',6'} = 2.2, ³*J*_{6',7'} = 9.7, H-6'), 4.42 (d, ³*J*_{5,6} = 5.4, H-5), 4.22 (dd, ³*J*_{6',7'} = 2.7, ²*J* = 11.8, H_a-7'), 4.20 (dd, ³*J*_{3',4'} = 2.7, ³*J*_{2',3'} = 2.7, H-3), 4.0 (d, ²*J* = 8.9, H_{exo}-6), 3.85 (m, 3H, H_{endo}-6, H-4', H-1'), 3.75 (t, ³*J*_{2',3'} = 2.7, ³*J*_{1',2'} = 3.2, H-2'), 3.70 (dd, ³*J*_{6',7'} = 1.6, ²*J* = 11.8, H-7'), 3.55 (d, ³*J*_{5',6'} = 9.7, H-5'), 3.07 (m, H-3), 2.51 (m, H_{endo}-2), 2.13 (m, H_{exo}-2), 0.97, 0.97, 0.91, 0.88 (4s, 36H, 4 *t*-Bu), 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01 (8s, 24H, 4 Me₂Si). ¹³C NMR (100.6 MHz, CDCl₃) δ 206 (s, C-4), 102 (d, 173, C-1), 79.5 (d, 141, C-2'), 79.5 (d, 163, C-5), 73.2 (d, 147, C-1'), 70.2 (d, 146, C-4'), 67.3 (d, 141, C-3'), 66.8 (t, 106, C-6), 65.2 (d, 146, C-6'), 64.7 (d, 140, C-5'), 58.5 (t, 144.6, C-7'), 44.4 (d, 125, C-3), 32.2 (t, 128, C-2), 18.4, 18.3, 18.1, 18.0 (4s, 4 Me₂CSi), -4.4, -4.6, -4.8, -4.9, -5.0, -5.0, -5.3, -5.3, -5.5 (8q, 118, 4 Me₂Si). CIMS HR *m/z* found 799.4464 (calcd for C₃₇H₇₆O₉Si₄ + Na: 799.4442).

4.18. 1,6-Anhydro-3-C-{2,6-anhydro-3,4,5,7-1-deoxy-tetrakis-*O*-[(*tert*-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-ylidene}-2,3-dideoxy-β-D-glycero-hexopyran-4-ulose **24**

Methanesulfonyl chloride (98%, 0.370 mL, 4.76 mmol) was added to a stirred solution of **22** and **23** (0.74 g, 0.959 mmol) in dry pyridine (15 mL) containing DMAP (50 mg) under an Ar atmosphere. The mixture was stirred for 14 h and then quenched by the addition of 20% aq soln of CuSO₄·5H₂O solution (30 mL). The solution was extracted with CH₂Cl₂ (3 × 50 mL), and the combined organic phases washed with 2 M aq HCl (3 × 30 mL), dried over MgSO₄, and then concentrated in vacuo to yield **24** as an unstable colorless oil, which was used without further purification in the next step.

4.19. 1,6-Anhydro-3-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-*O*-[(*tert*-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-threo-hexopyran-4-ulose **25 and 1,6-anhydro-3-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-*O*-[(*tert*-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-erythro-hexopyran-4-ulose **26****

Raney Nickel (1 g) in aqueous suspension was added to a stirred solution of **24** (0.9 g, 1.19 mmol) in THF (5 mL). The mixture was stirred at 20 °C until complete conversion of **24** (TLC control). The mixture was diluted with Et₂O (200 mL) and filtrated through a pad of Celite. FC (9:0.5:0.5 light petroleum ether/Et₂O/CH₂Cl₂): 390 mg (43%) of **25**, and 400 mg (44%) of **26**.

Data of **25**: colorless oil. [α]₅₈₉²⁵ = -10, [α]₅₄₆²⁵ = -13, [α]₄₃₅²⁵ = -44, [α]₄₀₅²⁵ = -73 (c 0.21, CHCl₃). IR (film):

2955, 2895, 2855, 1730, 1470, 1255, 1095, 835, 775 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 5.70 (d, ³*J* = 5.4, H-1), 4.53 (dd, ³*J*_{5,6_{exo}} = 5.4, ³*J*_{5,6_{endo}} = 0.5, H-5), 4.19 (dd, ³*J*_{5',6'} = 2.7, ³*J*_{4',5'} = 6.5, H-5'), 4.15 (dd, ³*J*_{6',7'} = 9.7, ²*J* = 11.8, H_a-7'), 4.00 (d, ³*J*_{1',2'} = 10.5, H-2'), 3.88 (t, ³*J*_{6',7'} = 7.5, H-6'), 3.77 (dd, ²*J* = 7.3, ³*J* = 0.5, H_{endo}-6), 3.72 (dd, ³*J* = 3.2, H-4'), 3.72 (m, H_{exo}-6), 3.65 (m, H-7'), 3.49 (d, ³*J* = 3.5, H-3'), 2.92 (m, H-3), 2.68 (m, H_{exo}-2), 1.67 (dd, ²*J* = 12.9, ³*J* = 8.06, H_b-1'), 1.46 (m, H_a-1'), 1.30 (m, H_{endo}-2), 0.97, 0.97, 0.91, 0.88 (4s, 36H 4 *t*-Bu), 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01 (8s, 24H, 4Me₂Si). ¹³C NMR (100.6 MHz, CDCl₃) δ 213 (s, C-4), 100.1 (d, 173, C-1), 79 (d, 141, C-6'), 79 (d, 163, C-5), 74 (d, 147, C-3'), 74 (d, 146, C-4'), 67 (d, 141, C-5'), 67 (t, 106, C-6), 65 (d, 146, C-2'), 58 (d, 145, C-7'), 39 (d, 125, C-3), 36 (t, 128, C-2), 30 (t, 128, C-1'), 18.4, 18.3, 18.1, 18.0 (4s, 4 *t*-BuSi), -4.4, -4.6, -4.8, -4.9, -5.0, -5.0, -5.3, -5.3, -5.5 (8q, 118, 4Me₂Si). CIMS HR *m/z* found 783.4542 (calcd for C₃₇H₇₆O₈Si₄ + Na: 783.4515).

Data of **26**: colorless oil. IR (film) 2955, 2895, 2855, 1730, 1470, 1255, 1095, 835, 775 cm⁻¹. CIMS HR *m/z* found 783.4521 (calcd for C₃₇H₇₆O₈Si₄ + Na: 783.4515).

4.20. 1,6-Anhydro-3-C-{2,6-anhydro-1-deoxy-3,4,5,7-tetrakis-*O*-[(*tert*-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy-β-D-lyxo-hexopyranose **27**

A THF solution of LiBH₄ (0.56 mL, 1.13 mmol) was added dropwise to a solution of **25** (0.140 mg, 0.188 mmol) in THF (5 mL) at -78 °C. The mixture was stirred for 4 h, from -78 to 15 °C. A satd aq soln of NH₄Cl (25 mL) was then added. The reaction mixture was warmed to 20 °C at which point a satd soln of sodium potassium tartarate (25 mL) was added. The aqueous phase was then extracted with CH₂Cl₂ (3 × 100 mL). The combined organic phases were dried and concentrated in vacuo. FC (light petroleum ether/Et₂O 9:1) 110 mg (79%), colorless oil. [α]₅₈₉²⁵ = +4, [α]₅₄₆²⁵ = +7, [α]₄₃₅²⁵ = +9, [α]₄₀₅²⁵ = +11 (c 0.08, CHCl₃). IR (film) 3425, 2955, 2855, 1620, 1470, 1360, 1130, 865, 835, 775, 740 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 5.57 (s, H-1), 4.48 (m, H_{exo}-6), 4.54 (m, H-2'), 4.42 (t, ³*J*_{6',7'} = 4.6, H-6'), 4.29 (m, H-4'), 4.26 (m, H-4), 4.24 (m, H_a-7'), 3.95 (d, ³*J*_{5,6_{endo}} = 2.5, ³*J*_{3,5} = 6.8, ³*J*_{5,6_{exo}} = 9.6, H-5), 3.88 (t, ³*J*_{5',6'} = 3.1, H-5'), 3.73 (dd, ²*J* = 12.3, ³*J*_{5,6_{endo}} = 2.5, H_{endo}-6), 3.70 (ddd, ³*J* = 2.5, ³*J*_{6',7'} = 1.6, H_b-7'), 3.46 (d, ³*J*_{3',4'} = 3.7, H-3'), 2.99 (ddd, ³*J* = 6.8, ³*J* = 12.3, ³*J* = 18.5, H-3), 2.03 (m, H_a-1'), 1.99 (m, H_{endo}-2), 1.83 (m, H_b-1'), 1.66 (m, H_{endo}-2), 0.97, 0.97, 0.91, 0.88 (4s, 36H, 4 *t*-Bu), 0.15, 0.14, 0.14, 0.12, 0.08, 0.07, 0.01, 0.01 (8s, 24H, 4Me₂Si). ¹³C NMR (100.6 MHz, CDCl₃) δ 101.5 (d, 173, C-1), 78.1 (d, 163, C-5), 75.6 (d, 141, C-6'), 74.4 (d, 147, C-3'), 73.8 (d, 141, C-5'), 69.2 (d, 146, C-4'), 67.5 (d, 141, C-4), 64.8 (d, 144.6, C-7'), 64.5 (d, 146, C-2'), 58.6 (t, 106, C-6), 36.5 (t, 128, C-2), 34.6 (t, 128, C-1'), 30.8 (d, 125, C-3), 18.4, 18.3, 18.1, 18.0 (4s, 4 *t*-BuSi), -4.4, -4.6, -4.8, -4.9, -5.0, -5.0, -5.3, -5.3, -5.5 (8q, 118, 4Me₂Si). CIMS HR *m/z* found 785.4662 (calcd for C₃₇H₇₈O₈Si₄ + Na: 785.4671).

4.21. 4,6-Di-O-acetyl-3-C-{7-O-acetyl-2,6-anhydro-1-deoxy-3,4,5-tri-O-[(*tert*-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-2,3-dideoxy- α , β -D-lyxo-hexopyranosyl acetate 28 α , β

A catalytic amount of triethylsilyl triflate (1.3 μ L) was added dropwise via a syringe to a solution of compound **27** (0.12 g, 0.157 mmol) in acetic anhydride (2 mL) cooled at 0°C. The mixture was stirred at 0°C for 30 min, and then a satd aq soln of NaHCO₃ added. The mixture was extracted with CH₂Cl₂ (3 $\times$ 10 mL). The organic layers were dried over MgSO₄, concentrated in vacuo and coevaporated with toluene in vacuo. The oily product obtained was used directly in the next step. $[\alpha]_{589}^{25} = +50$, $[\alpha]_{546}^{25} = +51$, $[\alpha]_{435}^{25} = +99$, $[\alpha]_{405}^{25} = +118$ (*c* 0.21, CHCl₃). CIMS HR *m/z* found 857.4334 (calcd for C₃₉H₇₄O₁₃Si₃ + Na: 857.4309).

4.22. 4,6-Di-O-acetyl-3-C-{7-O-acetyl-2,6-anhydro-1-deoxy-3,4,5-tri-O-[(*tert*-butyl)dimethylsilyl]-D-glycero-L-manno-heptitol-1-C-yl}-3-deoxy-D-galactal 3c

Silica gel (870 mg) was added to a solution of **28 α , β** (0.286 g, 0.315 mmol) in toluene (10 mL) and the mixture heated under reflux for 3 h. Filtration, washing with CH₂Cl₂ (100 mL), concentration in vacuo, FC (9:0.5:0.5, light petroleum ether/Et₂O/CH₂Cl₂) gave 160 mg (60%) of yellowish oil. $[\alpha]_{589}^{25} = -7$, $[\alpha]_{546}^{25} = -10$, $[\alpha]_{435}^{25} = -27$, $[\alpha]_{405}^{25} = -40$ (*c* 0.09, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 6.38 (dd, ³*J*_{1,2} = 6.2, ⁴*J*_{1,3} = 2.7, H-1), 5.49 (d, ³*J*_{3,4} = 3.4, H-4), 5.16 (dd, ³*J*_{6_{exo},6_{endo}} = 12.6, ³*J*_{5,6_{exo}} = 9.9, H_{exo}-6), 4.72 (dt, ³*J*_{1,2} = 6.2, ³*J*_{2,3} = 3.9, ⁴*J* = 1.6, C-H₂), 4.30–3.94 (m, 7H, H-5, H_{endo}-6, H-2', H-5', H-6', H_a-7', H_b-7'), 3.72 (t, ³*J*_{3',4'} = 4.0, H-4'), 3.40 (d, ³*J*_{3',4'} = 4.0, H-3'), 2.70 (br s, C-3), 2.10 (s, 6H, 2 Ac), 2.06 (s, 3H, Ac), 1.58 (m, H_a-1'), 1.25 (m, H_b-1'), 0.95, 0.94, 0.93 (3s, 27H, 3 *t*-Bu), 0.12, 0.12, 0.12, 0.10, 0.09, 0.06 (8s, 6H, 3 Me₂Si). ¹³C NMR (100.6 MHz, CDCl₃) δ 171.0, 170.7, 170.3 (3 Ac), 142.2 (d, 148, C-1), 104 (d, 146, C-2), 75.8 (d, 142, C-5'), 74.4 (d, 146, C-4'), 74.1 (d, 147, C-2'), 73.5 (d, 147, C-3'), 67.1 (d, 163, C-5), 65.6 (d, 142, C-6'), 65.0 (d, 142, -4), 63.4 (d, 145, C-7'), 60.2 (t, 106, C-6), 32.9 (d, 125, C-3), 32.3 (t, 128, C-1'), 26.1, 25.8, 25.6, (3s, 3 Me(Ac)), 21.1, 20.8, 20.7, (3s, 3 *t*-BuSi), -4.4, -4.5, -4.7, -4.72, -5.0, -5.1 (6q, 118, 3 Me₂Si). CIMS HR *m/z* found 797.4151 (calcd for C₃₇H₇₀O₁₁-Si₃ + Na: 797.4123).

Acknowledgements

We are grateful to the Swiss National Science Foundation (Grant No. 200020-100002), and the 'Office Fédéral de l'Éducation et de la Science' (Bern, COST D13/0001/99) for generous support. We thank the University of Lausanne and Mrs. Antoinette Charon for a *Peace* grant in favor of L.A. We thank also Prof. I. Robina, Universidad de Sevilla, Spain, for discussions and help with the HRMS. We thank also Mr. M. Rey, F. Sepúlveda and Miss C. Bühlmann for technical help.

References

- Rademacher, T. W.; Parekh, R. B.; Dwek, R. A. *Annu. Rev. Biochem.* **1988**, *57*, 785–838; Lis, H.; Sharon, N. *Eur. J. Biochem.* **1993**, *218*, 1–27; Hart, G. W. *Curr. Opin. Cell. Biol.* **1992**, *4*, 1017–1023; Varki, A.; Freeze, H. H. In *Subcellular Biochemistry*; Maddy, A. H., Harris, J. R., Eds.; Plenum: New York, 1994; p 71; Sears, P.; Wong, C.-H. *Angew. Chem., Int. Ed.* **1999**, *38*, 2301–2324.
- Bertozzi, C. R.; Kiessling, L. L. *Science (Washington, DC)* **2001**, *291*, 2357–2364; Rudd, P. M.; Elliott, T.; Cresswell, P.; Wilson, I. A.; Dwek, R. A. *Science (Washington, DC)* **2001**, *291*, 2370–2376; *Glycosciences: Status and Perspectives*; Gabius, H.-J., Gabius, S., Eds.; Chapman & Hall: London, U.K., 1997; Sears, P.; Wong, C.-H. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 12086–12093; Kiessling, L. L.; Pohl, N. L. *Chem. Biol.* **1996**, *3*, 71–77; Beuth, J.; Ko, H. L.; Pulverer, G.; Uhlenbruck, H.; Pichlmaier, H. *Glycoconjugate J.* **1995**, *12*, 1–6; Lasky, L. A. *Annu. Rev. Biochem.* **1995**, *64*, 113–139; Toyokuni, T.; Singhal, A. K. *Chem. Soc. Rev.* **1995**, *24*, 231–242; Varki, A. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 7390–7397; Feizi, T. *Curr. Opin. Struct. Biol.* **1993**, *3*, 701–710; Hakkamori, S. *Curr. Opin. Immun.* **1991**, *3*, 646–653; Wharton, S. A.; Weis, W.; Skehel, J. J.; ; Wiley, D. C. *The Influenza Virus*; Plenum: New York, 1989.
- Alper, J. *Science (Washington, DC)* **2001**, *291*, 2338–2343; Bols, M. *Acc. Chem. Res.* **1998**, *31*, 1–8; Barchi, J. J. *Curr. Pharm. Des.* **2000**, *6*, 485–501; Musser, J. H.; Anderson, M. B.; Fugedi, P. *Pharm. News* **1996**, *3*, 11–17; Mulligan, M. S.; Paulson, J. C.; DeFrees, S.; Zheng, Z. L.; Lowe, J. B.; Ward, P. A. *Nature (London)* **1993**, *364*, 149–151; Ragupathi, G.; Howard, L.; Cappello, S.; Koganty, R. R.; Qiu, D.; Longenecker, B. M.; Reddish, M. A.; Lloyd, K. O.; Livingston, P. O. *Cancer Immunol. Immunother.* **1999**, *48*, 1–8; MacLean, G. D.; Longenecker, B. M. *Can. J. Oncol.* **1994**, *4*, 249–254; MacLean, G. D.; Reddish, M.; Koganty, R. R.; Wong, T.; Gandhi, S.; Smolenski, M.; Samuel, J.; Nabholz, N. M.; Longenecker, B. M. *Cancer Immunol. Immunother.* **1993**, *36*, 215–222; Platt, F. M.; Neises, G. R.; Reinkensmeier, G.; Townsend, M. J.; Perry, V. H.; Proia, R. L.; Winchester, B.; Dwek, R. A.; Butters, T. D. *Science (Washington, DC)* **1997**, *276*, 428–431.
- Levy, D. E.; Tang, C. *Tetrahedron Organic Chemistry Series*. In *The Chemistry of C-Glycosides*; Baldwin, J. E., Magnus, P. D., Eds.; Pergamon-Elsevier Science: Oxford, 1995; Postma, M. H. D. *C-Glycoside Synthesis*; Boca Raton, FL: CRC, 1995; Du, Y.; Linhardt, R. J.; Vlahov, I. R. *Tetrahedron* **1998**, *54*, 9913–9959.
- Springer, G. F. *Science (Washington, DC)* **1984**, *224*, 1198–1206; Jennings, H. J.; Ashton, F. E.; Gamian, A.; Michon, F.; Roy, R. *Can. Prog. Biotechnol.* **1987**, *3*, 149–156; Taylor-Papadimitriou, J.; Epenetos, A. A. *Trends Biotechnol.* **1994**, *12*, 227–233; MacLean, G. D.; Reddish, M. A.; Bowen-Yacyshyn, M. B.; Poppema, S.; Longenecker, B. M. *Cancer Invest.* **1994**, *12*, 46–56; Rye, P. D.; Bovin, N. V.; Vlasova, E. V.; Walker, R. A. *Glycobiology* **1995**, *5*, 385–389; Springer, G. F. *Crit. Rev. Oncol.* **1995**, *6*, 57–85; Ragupathi, G. *Cancer Immunol. Immunother.* **1996**, *43*, 152–157; Cooper, D. K. C.; Oriol, R. *Glycobiology in Xenotransplantation research*. In *Glycosciences*; Gabius, S., Ed.; Chapman & Hall: Weinheim, 1997; p 531; Kim, Y. J.; Varki, A. *Glycoconjugate J.* **1997**, *14*, 569–576; Hakkamori, S.; Zhang, Y. *Chem. Biol.* **1997**, *4*, 97–104; Hallberg, E. C.; Stokan, V.; Cairns, T. D. H.; Breimer, M. E.; Samuelsson, B. E. *Xenotransplantation* **1998**, *5*, 246–256;

- Hakomori, S. *Acta Anat.* **1998**, *161*, 79–90; Kuduk, S. D.; Schwarz, J. B.; Chen, X.-T.; Glunz, P. W.; Sames, D.; Ragupathi, G.; Livingston, P. O.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1998**, *120*, 12474–12485; Orntoft, T. F.; Vestergaard, E. M. *Electrophoresis* **1999**, *20*, 362–371; Lo-Man, R.; Bay, S.; Vichier-Guerre, S.; Deriaud, E.; Cantacuzene, D.; Leclerc, C. *Cancer Res.* **1999**, *59*, 1520–1524; Allen, J. R.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1999**, *121*, 10875–10882; Kuberan, B.; Linhardt, R. J. *Curr. Org. Chem.* **2000**, *4*, 653–677; Bousquet, E.; Spadaro, A.; Pappalardo, M. S.; Bernardini, R.; Romeo, R.; Panza, L.; Ronsisvalle, G. *J. Carbohydr. Chem.* **2000**, *19*, 527–541.
6. Pasquarello, C.; Demange, R.; Vogel, P. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 793–796; Pasquarello, C.; Picasso, S.; Demange, R.; Malissard, M.; Berger, E. G.; Vogel, P. *J. Org. Chem.* **2000**, *65*, 4251–4260.
7. Rodén, L. Metabolic Conjugation and Metabolic Hydrolysis; Fishman, W. E., Ed.; Academic, 1970; Vol. 2, pp 245–442; Stern, E. L.; Lindahl, B.; Rodén, L. *J. Biol. Chem.* **1971**, *246*, 5707–5715; Montreuil, J. *Adv. Carbohydr. Chem. Biochem.* **1980**, *37*, 157–223.
8. Hirst, E. L.; Perlin, A. S. *J. Chem. Soc.* **1954**, 2622–2627; Bailey, R. W. *Oligosaccharides*; Pergamon: Oxford, 1965, p 48; Aspinall, G. O.; Young, R. *J. Chem. Soc.* **1965**, 3003–3004; Hirst, E. L.; Mackie, W.; Percival, E. *J. Chem. Soc.* **1965**, 2958–2967; Parikh, V. M.; Jones, J. K. N. *Can. J. Chem.* **1966**, *44*, 1531–1539; Rodén, L.; Smith, R. *J. Biol. Chem.* **1966**, *241*, 5949–5954; Lindberg, B.; Rodén, L.; Silvester, B. G. *Carbohydr. Res.* **1966**, *2*, 413–417; Michalski, J.-C.; Bouquelet, S.; Montreuil, J.; Strecker, G.; Dulac, O.; Munnich, A. *Clin. Chim. Acta* **1984**, *137*, 43–51.
9. Fritzsims, B. J.; Leblanc, Y.; Chan, N.; Rokach, J. *J. Am. Chem. Soc.* **1988**, *110*, 5229–5231; Halcomb, R. L.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1989**, *111*, 6661–6666; Sebesta, D. P.; Roush, W. R. *J. Org. Chem.* **1992**, *57*, 4799–4802; Liu, K. K. C.; Danishefsky, S. J.; McCluse, K. F.; Randolph, J. T.; Ruggeri, R. B. *Science* **1993**, *260*, 1307–1309; Wang, J.; Wurster, J. A.; Wilson, L. J.; Liotta, D. *Tetrahedron Lett.* **1993**, *34*, 4881–4884; Liu, K. K.-C.; Danishefsky, S. L. *J. Org. Chem.* **1994**, *59*, 1892–1894; Randolph, J. T.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1995**, *117*, 5693–5700; Danishefsky, S. J.; Behar, W.; Randolph, J. I.; Llod, K. O. *J. Am. Chem. Soc.* **1995**, *117*, 5701–5711; Kim, H.; Men, H.; Lee, C. *J. Am. Chem. Soc.* **2004**, *126*, 1336–1337; Geiger, J.; Barroca, N.; Schmidt, R. R. *Synthesis* **2004**, 836–840.
10. Marouka, K.; Nonoshita, K.; Itoh, T.; Yamamoto, H. *Chem. Lett.* **1987**, 2215–2216; Casiraghi, G.; Cornia, M.; Rassu, G.; Zetta, L.; Gasparri Fava, G.; Ferrari Belicchi, M. *Carbohydr. Res.* **1989**, *191*, 243–251; Daves, G. D., Jr. *Acc. Chem. Res.* **1990**, *23*, 201–206; Dubois, E.; Beau, J.-M. *Carbohydr. Res.* **1992**, *228*, 103–120; Toshima, K.; Ishizuka, T.; Matsuo, G.; Nakata, M. *Tetrahedron Lett.* **1994**, *35*, 5673–5676; Lopez, J. C.; Gomez, A. M.; Fraser-Reid, B. *J. Org. Chem.* **1995**, *60*, 3871–3878; Thorn, S. N.; Gallagher, T. *Synlett* **1996**, 185–187; Williams, L. J.; Garbaccio, R. M.; Danishefsky, S. J. *Carbohydr. Chem. Biol.* **2000**, *1*, 61–92; Berber, H.; Brigaud, T.; Lefebvre, O.; Plantier-Royan, R.; Portella, C. *Chemistry (Weinheim)* **2001**, *7*, 903–909; Ramnauth, J.; Poulin, P.; Rakhit, S.; Maddaford, S. P. *Org. Lett.* **2001**, *3*, 2013–2015; Yadav, J. S.; Reddy, B. V.; Chandraiah, L.; Reddy, K. S. *Carbohydr. Res.* **2001**, 221–224; Hayashi, M. *Recent Res. Develop. Org. Bioorg. Chem.* **2001**, *4*, 63–87; Parrish, J. D.; Little, R. D. *Org. Lett.* **2002**, *4*, 1439–1442; Hayashi, M.; Kawabata, W.; Nakayama, S.-Z. *Chirality* **2003**, *15*, 10–16; Seeberger, P. H. *Chem. Commun.* **2003**, 1115–1121; Geiger, J.; Barroca, N.; Schmidt, R. R. *Synlett* **2004**, 836–840; Kim, H.; Men, H.; Lee, C. *J. Am. Chem. Soc.* **2004**, *126*, 1336–1337.
11. For other methods of synthesis of C(1→3)-disaccharides, see for example: Miller, W. H.; Ryckman, D. M.; Goekjian, P. G.; Wang, Y.; Kishi, Y. *J. Org. Chem.* **1988**, *53*, 5580–5582; Wang, Y.; Goekjian, P. G.; Ryckman, D. M.; Kishi, Y. *J. Org. Chem.* **1988**, *53*, 4151–4153; Paton, R. M. In *Carbohydrate Mimics*; Chapleur, Y., Ed.; Wiley-VCH, Verlag GmbH: Germany, 1998; pp 49–66, and references cited therein; Vogel, P.; Ferritto, R.; Kraehenbuehl, A. K.; Baudat, A. In *Carbohydrate Mimics*; Chapleur, Y., Ed.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 1998; pp 19–46, and references cited therein; Krintel, S. L.; Jimenez-Barbero, J.; Skrydstrup, T. *Tetrahedron Lett.* **1999**, *40*, 7565–7568; Gerber, P.; Vogel, P. *Tetrahedron Lett.* **1999**, *40*, 3165–3168; Skrydstrup, T.; Vauzeilles, B.; Beau, J.-M. *Carbohydrates in Chemistry and Biology*; Ernst, B., Hart, G. W., Sinaÿ, P., Eds.; Wiley-VCH: Weinheim, Germany, 2000; Vol. 1, pp 495–530; Liu, L.; Postema, M. H. D. *J. Am. Chem. Soc.* **2001**, *123*, 8602–8603; Liu, L.; McKee, M.; Postema, M. H. D. *Curr. Org. Chem.* **2001**, *5*, 1133; Vauzeilles, B.; Sinaÿ, P. *Tetrahedron Lett.* **2001**, *42*, 7269–7272; Munch-Mikkelsen, L.; Krintel, S. L.; Jimenez-Barbero, J.; Skrydstrup, T. *J. Org. Chem.* **2002**, *67*, 6297–6308; Postema, M. H. D.; Piper, J. L.; Liu, L.; Shen, J.; Faust, M.; Andreana, P. *J. Org. Chem.* **2003**, *68*, 4748–4754; Stepánek, P.; Kniesz, L.; Dvorákova, H.; Vojlisek, P. *Synlett* **2003**, 963–966; Cardona, F.; Goti, A.; Brandi, A. *Org. Lett.* **2003**, *5*, 1475–1478; Stepánek, P.; Vich, O.; Kniesz, L.; Dvorákova, H.; Vojlisek, P. *Tetrahedron: Asymmetry* **2004**, *15*, 1033–1041; Dondoni, A.; Marra, A. *Chem. Rev.* **2004**, *104*, 2557–2599.
12. Schmidt, R. R.; Beyerbach, A. *Liebigs Ann. Chem.* **1992**, 983–986.
13. Itoh, A.; Ozawa, S.; Oshima, K.; Nozaki, H. *Tetrahedron Lett.* **1980**, *21*, 361–364; Itoh, A.; Ozawa, S.; Oshima, K.; Nozaki, H. *Bull. Chem. Soc. Jpn.* **1981**, *54*, 274–278.
14. Horton, D.; Roski, J. P.; Norris, P. *J. Org. Chem.* **1996**, *61*, 3783–3793; Witczak, Z. J. *Levoglucosenone and Levoglucosans; Chemistry and Applications*; ATL: Science Publishers: Mount Prospect, IL, USA, 1994.
15. Zhu, Y.-H.; Demange, R.; Vogel, P. *Tetrahedron: Asymmetry* **2000**, *11*, 263–282, When isolevoglucosenone **4** and aldehyde **5a** were treated with Me₂AlSPH, a product of condensation was obtained at –78 °C. Its direct reduction with various hydride reagents [LiBH₄, (*i*-Bu)₂AlH, Na(CN)BH₃] also furnished **11**, but with a yield never surpassing 20% as several other undefined products were formed concurrently.
16. Jiménez-Barbero, J.; Demange, P.; Schenk, K.; Vogel, P. *J. Org. Chem.* **2001**, *66*, 5132–5138.
17. Kobertz, N. R.; Bertozzi, C. R.; Bednarski, M. D. *Tetrahedron Lett.* **1992**, 737–740; Kobertz, W. R.; Bertozzi, C. R.; Bednarski, M. D. *J. Org. Chem.* **1996**, *61*, 1894–1897.
18. For alternative synthesis of **5**, see: Dondoni, A.; Boscarato, A.; Zuurmond, H. *Tetrahedron Lett.* **1996**, *37*, 7587–7590; Dondoni, A.; Scherrmann, M.-C. *J. Org. Chem.* **1994**, *59*, 6404–6412; Dondoni, A. *Synthesis* **1998**, 1681–1706; Dondoni, A.; Giovannini, P. P. *Synthesis* **2000**, 22, 1701–1706; Dondoni, A. *Pure Appl. Chem.* **2000**, *72*, 1577–1588.
19. Zimmerman, H. E.; Traxler, M. D. *J. Am. Chem. Soc.* **1957**, *79*, 1920–1923.
20. Rychnovsky, S. D.; Rogers, B. N.; Richardson, T. *Acc. Chem. Res.* **1998**, *31*, 9.

21. Lemieux, R. U.; Levine, S. *Can. J. Chem.* **1964**, *42*, 1417–1480; Lemieux, R. U.; Fraser-Reid, B. *Can. J. Chem.* **1965**, *43*, 1468–1473.
22. Thiem, J.; Karl, H.; Schwenter, J. *Synthesis* **1978**, 696–698; Thiem, J.; Ossowski, P. *J. Carbohydr. Chem.* **1984**, *3*, 287–313.
23. For similar difficulties, see for example: Friesen, R. W.; Danishefsky, S. J. *Tetrahedron* **1990**, *46*, 103–112; Kottenhahn, M.; Kessler, H. *Liebigs Ann. Chem.* **1991**, *22*, 727–744.
24. Tatsuta, K.; Fujimoto, F.; Kinoshita, M. *Carbohydr. Res.* **1977**, *54*, 85–104; Friesen, R. W.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1989**, *111*, 6656–6660.
25. Moreno-Vargas, A. J.; Vogel, P. *Tetrahedron: Asymmetry* **2003**, *14*, 3173–3176.